U.S. patent application number 17/469359 was filed with the patent office on 2021-12-30 for antibodies to human programmed death receptor pd-1.
This patent application is currently assigned to Merck Sharp & Dohme B.V.. The applicant listed for this patent is Merck Sharp & Dohme B.V.. Invention is credited to Gregory John Carven, Gradus Johannes Dulos, Hans van Eenennaam.
Application Number | 20210403560 17/469359 |
Document ID | / |
Family ID | 1000005827968 |
Filed Date | 2021-12-30 |
United States Patent
Application |
20210403560 |
Kind Code |
A1 |
Carven; Gregory John ; et
al. |
December 30, 2021 |
ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1
Abstract
Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and
their variable region sequences are disclosed. A method of
increasing the activity (or reducing downmodulation) of an immune
cell through the PD-1 pathway is also disclosed.
Inventors: |
Carven; Gregory John;
(Maynard, MA) ; van Eenennaam; Hans; (Nijmegen,
NL) ; Dulos; Gradus Johannes; (Elst, NL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Merck Sharp & Dohme B.V. |
Rahway |
NJ |
US |
|
|
Assignee: |
Merck Sharp & Dohme
B.V.
Rahway
NJ
|
Family ID: |
1000005827968 |
Appl. No.: |
17/469359 |
Filed: |
September 8, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15810892 |
Nov 13, 2017 |
11117961 |
|
|
17469359 |
|
|
|
|
14576448 |
Dec 19, 2014 |
9834605 |
|
|
15810892 |
|
|
|
|
13719756 |
Dec 19, 2012 |
8952136 |
|
|
14576448 |
|
|
|
|
12663950 |
Jun 21, 2010 |
8354509 |
|
|
PCT/US2008/007463 |
Jun 13, 2008 |
|
|
|
13719756 |
|
|
|
|
60944583 |
Jun 18, 2007 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
G01N 2800/52 20130101;
C07K 2317/92 20130101; G01N 2333/55 20130101; G01N 33/57488
20130101; G01N 33/6869 20130101; C07K 16/2803 20130101; C07K
2317/565 20130101; C07K 16/2818 20130101; C07K 2317/24 20130101;
C07K 2317/76 20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; G01N 33/574 20060101 G01N033/574; G01N 33/68 20060101
G01N033/68 |
Claims
1-23. (canceled)
24. A method of increasing the activity of an immune cell,
comprising contacting the immune cell with a monoclonal antibody
which binds to human programmed death receptor 1 (hPD-1), wherein
the antibody blocks the binding of human PD-L1 and human PD-L2 to
hPD-1 and comprises: a. three light chain CDRs having the amino
acid sequences set forth in SEQ ID NOs: 9, 10 and 11 and b. three
heavy chain CDRs having the amino acid sequences set forth in SEQ
ID NOs: 12, 13 and 14.
25. A method of increasing the activity of an immune cell for the
treatment of cancer in a human patient in need thereof, comprising
administering to the patient a therapeutically effective amount of
a monoclonal antibody which binds to human programmed death
receptor 1 (hPD-1), wherein the antibody blocks the binding of
human PD-L1 and human PD-L2 to hPD-1 and comprises: a. three light
chain CDRs having the amino acid sequences set forth in SEQ ID Nos:
9, 10 and 11 and b. three heavy chain CDRs having the amino acid
sequences set forth in SEQ ID Nos: 12, 13 and 14.
26. The method of claim 25, wherein the cancer is melanoma, renal
cancer, prostate cancer, breast cancer, colon cancer, lung cancer,
esophageal cancer, squamous cell carcinoma of the head and neck,
liver cancer, ovarian cancer, cervical cancer, thyroid cancer,
glioblastoma, or lymphoma.
27. The method of claim 25, wherein the antibody is used in
combination with an anti-neoplastic agent or immunogenic agent.
28. The method of claim 25, wherein the antibody is used in
combination with chemotherapy, radiotherapy, or surgery.
29. The method of claim 25, wherein the antibody is used in
combination with an antibody that binds to VEGF, an antibody that
binds to EGFR, an antibody that binds to Her2/neu, an antibody that
binds to a VEGF receptor, an antibody that binds to CTLA-4, an
antibody that binds to OX-40, an antibody that binds to 4-1BB, an
antibody that binds to ICOS, an antibody that binds to CD20, or an
antibody that binds to CD40.
30. The method of claim 25, wherein the antibody blocks binding of
human PD-L1 and human PD-L2 to human PD-1 with an IC50 of about 1
nM or lower, wherein the IC50 is measured using an FMAT competition
assay.
31. The method of claim 25, wherein the antibody binds PD-1 with a
K.sub.D of about 30 .mu.M or lower, wherein the binding is
determined using bio-light interferometry.
32. The method of claim 25, wherein the antibody is an IgG4
isotype.
33. The method of claim 25, wherein the wherein the antibody is a
human antibody, a humanized antibody or a chimeric antibody.
34. The method of claim 25, wherein the antibody blocks binding of
human PD-L1 and human PD-L2 to human PD-1 with an IC50 of about 1
nM or lower, wherein the IC50 is measured using a FACS assay.
35. The method of claim 25, wherein the antibody comprises a light
chain variable region comprising the amino acid sequence set forth
in SEQ ID NO:6 and a heavy chain variable region comprising the
amino acid sequence set forth in SEQ ID NO:5.
36. The method of claim 35, wherein the cancer is melanoma, renal
cancer, prostate cancer, breast cancer, colon cancer, lung cancer,
esophageal cancer, squamous cell carcinoma of the head and neck,
liver cancer, ovarian cancer, cervical cancer, thyroid cancer,
glioblastoma, or lymphoma.
37. The method of claim 35, wherein the antibody is used in
combination with an anti-neoplastic agent or immunogenic agent.
38. The method of claim 35, wherein the antibody is used in
combination with chemotherapy, radiotherapy, or surgery.
39. The method of claim 35, wherein the antibody is used in
combination with an antibody that binds to VEGF, an antibody that
binds to EGFR, an antibody that binds to Her2/neu, an antibody that
binds to a VEGF receptor, an antibody that binds to CTLA-4, an
antibody that binds to OX-40, an antibody that binds to 4-1BB, an
antibody that binds to ICOS, an antibody that binds to CD20, or an
antibody that binds to CD40.
40. The method of claim 35, wherein the antibody blocks binding of
human PD-L1 and human PD-L2 to human PD-1 with an IC50 of about 1
nM or lower, wherein the IC50 is measured using an FMAT competition
assay.
41. The method of claim 35, wherein the antibody binds PD-1 with a
K.sub.D of about 30 .mu.M or lower, wherein the binding is
determined using bio-light interferometry.
42. The method of claim 35, wherein the antibody is an IgG4
isotype.
43. The method of claim 35, wherein the antibody is a human
antibody, a humanized antibody or a chimeric antibody.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional application of U.S. Ser.
No. 15/810,892, filed Nov. 13, 2017, currently pending, which is a
divisional application of U.S. Ser. No. 14/576,448, filed Dec. 19,
2014, now U.S. Pat. No. 9,834,605, which is a divisional
application of Ser. No. 13/719,756, filed Dec. 19, 2012, now U.S.
Pat. No. 8,952,136, which is a continuation application of U.S.
Ser. No. 12/663,950, filed Jun. 21, 2010, now U.S. Pat. No.
8,354,509, which is a .sctn. 371 National Stage Application of
International Application No. PCT/US2008/007463, international
filing date of Jun. 13, 2008, which claims the benefit of U.S.
Provisional Application Ser. No. 60/944,583, filed Jun. 18, 2007,
now expired.
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0002] The sequence listing of the present application is submitted
electronically via EFS-Web as an ASCII formatted sequence listing
with a file name "OR06827USDIV4-SEQLIST-28JUL2021", with a creation
date of Jul. 28, 2021, and a size of 38 KB. This sequence listing
submitted via EFS-Web is part of the specification and is herein
incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
[0003] Programmed death receptor 1 (PD-1) is an immunoinhibitory
receptor that is primarily expressed on activated T and B cells.
Interaction with its ligands has been shown to attenuate T-cell
responses both in vitro and in vivo. Blockade of the interaction
between PD-1 and one of its ligands, PD-L1, has been shown to
enhance tumor-specific CD8.sup.+ T-cell immunity and may therefore
be helpful in clearance of tumor cells by the immune system.
[0004] PD-1 (encoded by the gene Pdcd1) is an Immunoglobulin
superfamily member related to CD28, and CTLA-4. PD-1 has been shown
to negatively regulate antigen receptor signaling upon engagement
of its ligands (PD-L1 and/or PD-L2) The structure of murine PD-1
has been solved as well as the co-crystal structure of mouse PD-1
with human PD-L1 (Zhang, X. et al., Immunity 20: 337-347 (2004);
Lin et al., Proc. Natl. Acad. Sci. USA 105: 3011-6 (2008)). PD-1
and like family members are type I transmembrane glycoproteins
containing an Ig Variable-type (V-type) domain responsible for
ligand binding and a cytoplasmic tail that is responsible for the
binding of signaling molecules. The cytoplasmic tail of PD-1
contains two tyrosine-based signaling motifs, an ITIM
(immunoreceptor tyrosine-based inhibition motif) and an ITSM
(immunoreceptor tyrosine-based switch motif).
[0005] Following T cell stimulation, PD-1 recruits the tyrosine
phosphatase SHP-2 to the ITSM motif within its cytoplasmic tail,
leading to the dephosphorylation of effector molecules such as CD3
zeta, PKC theta and ZAP70 that are involved in the CD3 T cell
signaling cascade. The mechanism by which PD-1 downmodulates T cell
responses is similar to, but distinct from that of CTLA-4, as both
molecules regulate an overlapping set of signaling proteins (Parry
et al., Mol. Cell Biol. 25: 9543-9553.). Bennett and coworkers have
shown that PD-1-mediated inhibition of T-cell signaling is only
effective when both activating and inhibitory signals are on the
same surface, indicating that the PD-1 signaling mechanism is
spatiotemporally determined (Bennett F. et al., J Immunol.
170:711-8 (2003)).
[0006] PD-1 was shown to be expressed on activated lymphocytes
(peripheral CD4+ and CD8.sup.+ T cells, B cells and monocytes) and
has also been shown to be expressed during thymic development on
CD4.sup.-CD8.sup.- (double negative) T cells as well as NK-T
cells.
[0007] The ligands for PD-1 (PD-L1 and PD-L2) are constitutively
expressed or can be induced in a variety of cell types, including
non-hematopoietic tissues as well as various tumor types. PD-L1 is
expressed on B, T, myeloid and dendritic cells (DCs), but also on
peripheral cells, like microvascular endothelial cells and
non-lymphoid organs like heart, lung etc. In contrast, PD-L2 is
only found on macrophages and DCs. The expression pattern of PD-1
ligands is suggestive of a role for PD-1 in maintaining peripheral
tolerance and may serve to regulate self-reactive T- and B-cell
responses in the periphery. Both ligands are type I transmembrane
receptors containing both IgV- and IgC-like domains in the
extracellular region. Both ligands contain short cytoplasmic
regions with no known signaling motifs.
[0008] To date, numerous studies have shown that interaction of
PD-1 with its ligands leads to the inhibition of lymphocyte
proliferation in vitro and in vivo. Disruption of the PD-1/PD-L1
interaction has been shown to increase T cell proliferation and
cytokine production and block progression of the cell cycle.
Initial analysis of Pdcd1.sup.-/- mice did not identify any drastic
immunological phenotype. However aged mice developed spontaneous
autoimmune diseases which differ according to the strain onto which
the Pdcd1 deficiency was backcrossed. These include lupus-like
proliferative arthritis (C57BL/6) (Nishimura H. et al., Int.
Immunol. 10: 1563-1572 (1998)), fatal cardiomyopathy (BALB/c)
(Nishimura H. et al., Science 291: 319-322 (2001)) and type I
diabetes (NOD) (Wang J. et al., Proc. Natl. Acad. Sci. U.S.A 102:
11823-11828 (2005)). Overall, analysis of the knockout animals has
led to the understanding that PD-1 functions mainly in inducing and
regulating peripheral tolerance. Thus, therapeutic blockade of the
PD-1 pathway may be helpful in overcoming immune tolerance. Such
selective blockade may be of use in the treatment of cancer or
infection as well as in boosting immunity during vaccination
(either prophylactic or therapeutic).
[0009] The role of PD-1 in cancer is established in the literature.
It is known that tumor microenvironment can protect tumor cells
from efficient immune destruction. PD-L1 has recently been shown to
be expressed on a number of mouse and human tumors (and is
inducible by IFN gamma on the majority of PD-L1 negative tumor cell
lines) and is postulated to mediate immune evasion (Iwai Y. et al.,
Proc. Natl. Acad. Sci. U.S.A. 99: 12293-12297 (2002); Strome S. E.
et al., Cancer Res., 63: 6501-6505 (2003).
[0010] In humans, expression of PD-1 (on tumor infiltrating
lymphocytes) and/or PD-L1 (on tumor cells) has been found in a
number of primary tumor biopsies assessed by immunohistochemistry.
Such tissues include cancers of the lung, liver, ovary, cervix,
skin, colon, glioma, bladder, breast, kidney, esophagus, stomach,
oral squamous cell, urothelial cell, and pancreas as well as tumors
of the head and neck (Brown J. A. et al., J. Immunol. 170:
1257-1266 (2003); Dong H. et al., Nat. Med. 8: 793-800 (2002);
Wintterle et al., Cancer Res. 63: 7462-7467 (2003); Strome S. E. et
al., Cancer Res., 63: 6501-6505 (2003); Thompson R. H. et al.,
Cancer Res. 66: 3381-5 (2006); Thompson et al., Clin. Cancer Res.
13: 1757-61 (2007); Nomi T. et al., Clin. Cancer Res. 13: 2151-7.
(2007)). More strikingly, PD-ligand expression on tumor cells has
been correlated to poor prognosis of cancer patients across
multiple tumor types (reviewed in Okazaki and Honjo, Int. Immunol.
19: 813-824 (2007)).
[0011] Blockade of the PD-1/PD-L1 interaction could lead to
enhanced tumor-specific T-cell immunity and therefore be helpful in
clearance of tumor cells by the immune system. To address this
issue, a number of studies were performed. In a murine model of
aggressive pancreatic cancer, T. Nomi et al. (Clin. Cancer Res. 13:
2151-2157 (2007)) demonstrated the therapeutic efficacy of
PD-1/PD-L1 blockade. Administration of either PD-1 or PD-L1
directed antibody significantly inhibited tumor growth. Antibody
blockade effectively promoted tumor reactive CD8.sup.+ T cell
infiltration into the tumor resulting in the up-regulation of
anti-tumor effectors including IFN gamma, granzyme B and perform.
Additionally, the authors showed that PD-1 blockade can be
effectively combined with chemotherapy to yield a synergistic
effect. In another study, using a model of squamous cell carcinoma
in mice, antibody blockade of PD-1 or PD-L1 significantly inhibited
tumor growth (Tsushima F. et al., Oral Oncol. 42: 268-274
(2006)).
[0012] In other studies, transfection of a murine mastocytoma line
with PD-L1 led to decreased lysis of the tumor cells when
co-cultured with a tumor-specific CTL clone. Lysis was restored
when anti-PD-L1 mAb was added (Iwai Y. et al., Proc. Natl. Acad.
Sci. U.S.A. 99: 12293-12297 (2002)). In vivo, blocking the
PD1/PD-L1 interaction was shown to increase the efficacy of
adoptive T cell transfer therapy in a mouse tumor model (Strome S.
E. et al., Cancer Res. 63: 6501-6505 (2003)). Further evidence for
the role of PD-1 in cancer treatment comes from experiments
performed with PD-1 knockout mice. PD-L1 expressing myeloma cells
grew only in wild-type animals (resulting in tumor growth and
associated animal death), but not in PD-1 deficient mice (Iwai Y.
et al., Proc. Natl. Acad. Sci. U.S.A. 99: 12293-12297 (2002)).
[0013] In human studies, R. M. Wong et al. (Int. Immunol. 19:
1223-1234 (2007)) showed that PD-1 blockade using a fully human
anti-PD-1 antibody augmented the absolute numbers of tumor-specific
CD8+ T cells (CTLs) in ex vivo stimulation assays using vaccine
antigens and cells from vaccinated individuals. In a similar study,
antibody blockade of PD-L1 resulted in enhanced cytolytic activity
of tumor-associated antigen-specific cytotoxic T cells and
increased cytokine production by tumor specific TH cells (Blank C.
et al., Int. J Cancer 119: 317-327 (2006)). The same authors showed
that PD-L1 blockade augments tumor-specific T cell responses in
vitro when used in combination with anti-CTLA-4 blockade.
[0014] Overall, the PD-1/PD-L1 pathway is a well-validated target
for the development of antibody therapeutics for cancer treatment.
Anti-PD-1 antibodies may also be useful in chronic viral infection.
Memory CD8.sup.+ T cells generated after an acute viral infection
are highly functional and constitute an important component of
protective immunity. In contrast, chronic infections are often
characterized by varying degrees of functional impairment
(exhaustion) of virus-specific T-cell responses, and this defect is
a principal reason for the inability of the host to eliminate the
persisting pathogen. Although functional effector T cells are
initially generated during the early stages of infection, they
gradually lose function during the course of a chronic infection.
Barber et al. (Barber et al., Nature 439: 682-687 (2006)) showed
that mice infected with a laboratory strain of LCMV developed
chronic infection resulting in high levels of virus in the blood
and other tissues. These mice initially developed a robust T cell
response, but eventually succumbed to the infection upon T cell
exhaustion. The authors found that the decline in number and
function of the effector T cells in chronically infected mice could
be reversed by injecting an antibody that blocked the interaction
between PD-1 and PD-L1.
[0015] Recently, it has been shown that PD-1 is highly expressed on
T cells from HIV infected individuals and that receptor expression
correlates with impaired T cell function and disease progression
(Day et al., Nature 443:350-4 (2006).; Trautmann L. et al., Nat.
Med. 12: 1198-202 (2006)). In both studies, blockade of the ligand
PD-L1 significantly increased the expansion of HIV-specific,
IFN-gamma producing cells in vitro.
[0016] Other studies also implicate the importance of the PD-1
pathway in controlling viral infection. PD-1 knockout mice exhibit
better control of adenovirus infection than wild-type mice (Iwai et
al., J. Exp. Med. 198:39-50 (2003)). Also, adoptive transfer of
HBV-specific T cells into HBV transgenic animals initiated
hepatitis (Isogawa M. et al., Immunity 23:53-63 (2005)). The
disease state of these animals oscillates as a consequence of
antigen recognition in the liver and PD-1 upregulation by liver
cells.
BRIEF SUMMARY OF THE INVENTION
[0017] The invention provides isolated antibodies and antibody
fragments that bind to human and cyno PD-1. In some embodiments,
the antibody or antibody fragment blocks binding of human PD-L1 and
human PD-L2 to human PD-1. In some embodiments, the PD-1 antibody
or antibody fragment of the invention includes one or more CDRs
(antibody Complementarity--Determining Regions) selected from SEQ
ID NOs: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20; and in
further embodiments, includes one or more heavy chain CDRs of SEQ
ID NOs:12, 13, 14, 18, 19 and 20 and/or the light chain CDRs of SEQ
ID NOs: 9, 10, 11, 15, 16 and 17. In some embodiments, the antibody
or antibody fragment is a chimeric antibody, human antibody,
humanized antibody or a fragment thereof.
[0018] In one embodiment, the invention provides an isolated
antibody or antibody fragment which binds to human PD-1 comprising:
a light chain comprising CDRs SEQ ID NOs: 9, 10 and 11, or variants
of any said sequences; and/or a heavy chain comprising CDRs SEQ ID
NOs: 12, 13 and 14, or variants of any said sequences.
[0019] In another embodiment, the invention provides an isolated
antibody or antibody fragment which binds to human PD-1 comprising:
a light chain comprising CDRs SEQ ID NOs: 15, 16 and 17 or variants
of any said sequences; and/or a heavy chain comprising CDRs SEQ ID
NOs: 18, 19 and 20, or variants of any said sequences.
[0020] In one embodiment, the invention comprises an antibody or
antigen binding fragment comprising a heavy chain variable region
SEQ ID NO: 5 or a variant thereof, and/or a light chain variable
region comprising SEQ ID NO: 6 or a variant thereof.
[0021] In one embodiment, the invention comprises an anibody or
antigen binding fragment comprising a heavy chain variable region
SEQ ID NO: 7 or a variant thereof and/or a light chain variable
region comprising SEQ ID NO: 8 or a variant thereof.
[0022] In one embodiment, the invention comprises an anibody or
antigen binding fragment comprising a heavy chain variable region
comprising amino acid residues 20 to 139 of SEQ ID NO: 30 or a
variant thereof, and/or a light chain variable region comprising
amino acid residues 20 to 130 of SEQ ID NO: 32 or a variant
thereof.
[0023] In one embodiment, the invention comprises an anibody or
antigen binding fragment comprising a heavy chain variable region
comprising amino acid residues 20 to 139 of SEQ ID NO: 30 or a
variant thereof, and/or a light chain variable region comprising
amino acid residues 20 to 130 of SEQ ID NO: 33 or a variant
thereof.
[0024] In one embodiment, the invention comprises an anibody or
antigen binding fragment comprising a heavy chain variable region
comprising amino acid residues 20 to 139 of SEQ ID NO: 30 or a
variant thereof, and/or a light chain variable region comprising
amino acid residues 20 to 130 of SEQ ID NO: 34 or a variant
thereof.
[0025] In one embodiment, the invention comprises an anibody or
antigen binding fragment comprising a heavy chain variable region
comprising an amino acid sequence having at least 90% homology to
amino acid residues 20 to 139 of SEQ ID NO: 30; and/or a light
chain variable region comprising and an amino acid sequence having
at least 90% homology to amino acid residues 20 to 130 of SEQ ID
NO: 32, 33 or 34.
[0026] In one embodiment, the invention provides an isolated
antibody or antibody fragment which binds to human PD-1 comprising:
a heavy chain comprising amino acid residues 20 to 466 of SEQ ID
NO: 31 or a variant thereof, and/or a light chain comprising amino
acid residues 20 to 237 of SEQ ID NO: 36 or a variant thereof.
[0027] In one embodiment, the invention provides an isolated
antibody or antibody fragment which binds to human PD-1 comprising:
a heavy chain comprising the amino acid residues 20 to 466 of SEQ
ID NO: 31 or a variant thereof, and/or a light chain comprising the
amino acid residues 20 to 237 of SEQ ID NO: 37 or a variant
thereof.
[0028] In one embodiment, the invention provides an isolated
antibody or antibody fragment which binds to human PD-1 comprising:
a heavy chain comprising amino acid residues 20 to 466 of SEQ ID
NO: 31 or a variant thereof, and/or a light chain comprising amino
acid residues 20 to 237 of SEQ ID NO: 38 or a variant thereof.
[0029] In one embodiment, the invention provides an isolated
antibody or antibody fragment which binds to human PD-1 comprising:
a heavy chain comprising amino acid residues 20 to 469 of SEQ ID
NO: 35 or a variant thereof, and/or a light chain comprising amino
acid residues 20 to 237 of SEQ ID NO: 36 or a variant thereof.
[0030] In one embodiment, the invention provides an isolated
antibody or antibody fragment which binds to human PD-1 comprising:
a heavy chain comprising amino acid residues 20 to 469 of SEQ ID
NO: 35 or a variant thereof, and/or a light chain comprising amino
acid residues 20 to 237 of SEQ ID NO: 37 or a variant thereof.
[0031] In one embodiment, the invention provides an isolated
antibody or antibody fragment which binds to human PD-1 comprising:
a heavy chain comprising amino acid residues 20 to 469 of SEQ ID
NO: 35 or a variant thereof, and/or a light chain comprising amino
acid residues 20 to 237 of SEQ ID NO: 38 or a variant thereof.
[0032] In any of the above embodiments, the variant of the antibody
or antibody fragment of the invention may comprise one, two or
three conservatively modified amino acid substitutions.
[0033] In any of the above embodiments, the antibody or antibody
fragment of the invention may comprise a human heavy chain constant
region or a variant thereof, wherein the variant comprises up to 20
conservatively modified amino acid substitutions; and/or a human
light chain constant region or a variant thereof, wherein the
variant comprises up to 20 conservatively modified amino acid
substitutions. In some embodiments, the variant may comprise up to
10 conservatively modified amino acid substitutions. In some
embodiments, the variant may comprise up to 5 conservatively
modified amino acid substitutions. In some embodiments, the variant
may comprise up to 3 conservatively modified amino acid
substitutions. In any of the above embodiments, the human heavy
chain constant region or variant thereof may be of the IgG1 or IgG4
isotype.
[0034] In any of the above described embodiments, the antibody or
antibody fragment of the invention may bind human PD-1 with a
K.sub.D of about 100 pM or lower. In another embodiment, the
antibody or antibody fragment may bind human PD-1 with a K.sub.D of
about 30 pM or lower. In another embodiment, the antibody or
antibody fragment may bind human PD-1 with about the same K.sub.D
as an antibody having a heavy chain comprising the amino acid
sequence of SEQ ID NO: 31 and a light chain comprising the amino
acid sequence of SEQ ID NO: 32. In another embodiment, the antibody
or antibody fragment may bind human PD-1 with about the same
K.sub.D as an antibody having a heavy chain comprising the amino
acid sequence of SEQ ID NO: 31 and a light chain comprising the
amino acid sequence of SEQ ID NO: 33.
[0035] In any of the above described embodiments, the antibody or
antibody fragment of the invention may bind human PD-1 with a
k.sub.assoc of about 7.5.times.10.sup.5 1/Ms or faster. In one
embodiment, the antibody or antibody fragment may bind human PD-1
with a k.sub.assoc of about 1.times.10.sup.6 1/Ms or faster.
[0036] In any of the above described embodiments, the antibody or
antibody fragment may bind human PD-1 with a k.sub.dissoc of about
2.times.10.sup.-5 1/s or slower. In one embodiment, the antibody or
antibody fragment may bind human PD-1 with a k.sub.dissoc of about
2.7.times.10.sup.-5 1/s or slower. In one embodiment, the antibody
or antibody fragment may bind human PD-1 with a k.sub.dissoc of
about 3.times.10.sup.-5 1/s or slower.
[0037] K.sub.D, k.sub.assoc and k.sub.dissoc values can be measured
using any available method. In preferred embodiments, the
dissociation constant is measured using bio-light interferometry
(for example, the ForteBio Octet method described in Example 2). In
other preferred embodiments, the disassociation constant can be
measured using surface plasmon resonance (e.g. Biacore) or
Kinexa.
[0038] Further, in any of the above described embodiments, the
antibody or antibody fragment of the invention may block binding of
human PD-L1 or human PD-L2 to human PD-1 with an IC.sub.50 of about
1 nM or lower. The blockade of ligand binding can be measured and
the IC.sub.50 calculated using any method known in the art, for
example, the FACS or FMAT methods described in the Examples
herein.
[0039] The invention also comprises an antibody or antibody
fragment which competes for a binding epitope on human PD-1 with
any of the antibodies described above, and which blocks the binding
of human PD-L1 or human PD-L2 to human PD-1 with an IC.sub.50 of
about 1 nM or lower.
[0040] The invention also comprises an antibody or antibody
fragment which competes for a binding epitope on human PD-1 with
any of the antibodies described above, and which binds human PD-1
with a K.sub.D of about 100 pM or lower. In one embodiment, the
antibody or antibody fragment binds human PD-1 with a K.sub.D of
about 30 pM or lower.
[0041] The invention also comprises an antibody or antibody
fragment which competes for a binding epitope on human PD-1 with
any of the antibodies described above, and which binds human PD-1
with about the same K.sub.D as an antibody having a heavy chain
comprising the amino acid sequence of SEQ ID NO: 31 and a light
chain comprising the amino acid sequence of SEQ ID NO: 32.
[0042] The invention also comprises an antibody or antibody
fragment that competes for a binding epitope on human PD-1 with any
of the antibodies described above, and which binds human PD-1 with
about the same K.sub.D as an antibody having a heavy chain
comprising the amino acid sequence of SEQ ID NO: 31 and a light
chain comprising the amino acid sequence of SEQ ID NO: 33.
[0043] The invention also comprises an antibody or antibody
fragment which competes for a binding epitope on human PD-1 with
any of the antibodies described above, and which binds human PD-1
with a k.sub.assoc of about 7.5.times.10.sup.5 1/Ms or faster. In
one embodiment, the antibody or antibody fragment may bind human
PD-1 with a k.sub.assoc of about 1.times.10.sup.6 1/Ms or
faster.
[0044] The invention also comprises an antibody or antibody
fragment which competes for a binding epitope on human PD-1 with
any of the antibodies described above, and which binds human PD-1
with a k.sub.dissoc of about 2.times.10.sup.-5 1/s or slower. In
one embodiment, the antibody or antibody fragment may bind human
PD-1 with a k.sub.dissoc of about 2.7.times.10.sup.-5 1/s or
slower. In one embodiment, the antibody or antibody fragment may
bind human PD-1 with a k.sub.dissoc of about 3.times.10.sup.-5 1/s
or slower.
[0045] In some embodiments, the antibody or antibody fragments of
the invention are chimeric antibodies or fragments of chimeric
antibodies.
[0046] In some embodiments, the antibody or antibody fragments of
the invention are human antibodies or fragments of human
antibodies.
[0047] In some embodiments, the antibody or antibody fragments of
the invention are humanized antibodies or fragments of humanized
antibodies.
[0048] In some embodiments, the antibody fragments of the invention
are Fab, Fab', Fab'-SH, Fv, scFv, or F(ab')2 antibody
fragments.
[0049] In some embodiments, the antibody fragments of the invention
are diabodies.
[0050] The invention also comprises bispecific antibodies
comprising any one of the antibody or antibody fragments described
above that bind to human PD-1.
[0051] In some embodiments, the isolated anti-PD-1 antibodies and
antibody fragments of the invention increase T cell activation as
measured by typical means known to one skilled in the art
(including, without limitation, increased immune cell
proliferation, increased cytokine secretion or expression of
activation markers such as CD25 and/or CD69).
[0052] In any of the above described embodiments, the antibody or
antibody fragment of the invention may enhance the immune response
after stimulation with Staphylococcus Enterotoxin B or Tetanus
Toxoid ex vivo or in vivo. The increased immune activation may be
determined using methods known to anyone skilled in the art, for
example, quantifying proliferation of immune cells (such as T
cells) or cytokine production by immune cells (for example
production of IFN.gamma. or IL-2 by T cells).
[0053] The invention also comprises nucleic acids encoding the
anti-PD-1 antibodies and antibody fragments of the invention.
Included in the invention are nucleic acids encoding any one of the
amino acid sequences disclosed in SEQ ID NOS: 5 to 20 and 30-38
(with or without the leader sequences). Also included within the
invention are nucleic acids comprising SEQ ID NOS:1 to 4 and 21 to
29 (with or without the nucleic acids encoding the leader
sequences).
[0054] The invention also comprises cells and expression vectors
comprising nucleic acids encoding the antibodies or antibody
fragments of the invention. Further, the invention comprises a
method of producing an antibody or antibody fragment of the
invention comprising: (a) culturing the host cell comprising a
nucleic acid encoding an antibody or antibody fragment of the
invention in culture medium under conditions wherein the nucleic
acid sequence is expressed, thereby producing polypeptides
comprising the light and heavy chain variable regions; and (b)
recovering the polypeptides from the host cell or culture
medium.
[0055] The invention also comprises compositions comprising an
antibody or antibody fragment of the invention in combination with
a pharmaceutically acceptable carrier or diluent.
[0056] The invention also comprises a method of increasing the
activity of an immune cell, comprising administering to a subject
in need thereof a therapeutically effective amount of an antibody
or antibody fragment of the invention. In one embodiment, the
method may be used to treat cancer. In another embodiment, the
method may be use to treat an infection or infectious disease. In
yet another embodiment, the method may be used as a vaccine
adjuvant. In some embodiments, the method comprises further
administering a second therapeutic agent or treatment modality.
[0057] In some embodiments, the invention comprises a method of
increasing the activity of an immune cell, comprising administering
to a subject in need thereof a therapeutically effective amount of
an antibody or antibody fragment of the invention, and further
comprising measuring T cell activation ex vivo in a sample derived
from the subject, wherein an increase in T cell activity indicates
that the treatment should be continued. In other embodiments, the
invention comprises a method of increasing the activity of an
immune cell, comprising administering to a subject in need thereof
a therapeutically effective amount of an antibody or antibody
fragment of the invention, and further comprising measuring T cell
activation ex vivo in a sample derived from the subject, wherein an
increase in T cell activity predicts the likelihood that the
treatment will be successful. In one embodiment, the increase in T
cell activity is determined by: (i) measuring SEB induced
production of one or more cytokines selected from the group
consisting of: IL-2, TNF.alpha., IL-17, IFN.gamma., GM-CSF, RANTES,
IL-6, IL-8, IL-5 and IL-13; or (ii) measuring TT induced production
of a cytokine selected from the group consisting of: IL-2,
TNF.alpha., IL-17, IFN.gamma., GM-CSF, RANTES, IL-6, IL-8, IL-5 and
IL-13.
[0058] The invention also comprises the use of an anti-PD-1
antibody or antibody fragment of the invention for the preparation
of a medicament to increase immune response.
[0059] The invention also comprises the use of an anti-PD-1
antibody or antibody fragment of the invention for the preparation
of a medicament to treat cancer.
[0060] The invention also comprises the use of an anti-PD-1
antibody or antibody fragment of the invention as a vaccine
adjuvant.
[0061] The invention also comprises an immunoconjugate comprising
an anti-PD-1 antibody or antibody fragment of the invention, linked
to a therapeutic agent such as a bacterial toxin or a radiotoxin.
Non-limiting examples of cytotoxic agents include taxol,
cytochalasin B, mitomycin, etoposide and vincristine or other
antimetabolites, alkylating agents, antibiotics and
antimitotics.
[0062] The invention also comprises a method of increasing the
activity, or reducing the downmodulation, of an immune cell
comprising contacting the immune cell with any one of the
antibodies or antibody fragments of the invention. This method
could be used to treat cancer or infectious diseases (such as
chronic viral infections), or could be used as an adjuvant to a
prophylactic or therapeutic vaccine.
[0063] The invention also comprises a method of increasing an
immune response to an antigen, comprising contacting an immune cell
with an antigen and an anti-PD-1 antibody or an antibody fragment
such that an immune response to the antigen is increased or
enhanced. This method could be conducted in vivo (in a subject) or
ex vivo.
[0064] In some embodiments, an anti-PD-1 antibody or antibody
fragment may be combined with a second therapeutic agent or
treatment modality. In one embodiment, an anti-PD-1 antibody or
antibody fragment may be combined with cancer treatments involving
the application of recombinant cytokines or secreted immune
factors. Non-limiting examples of combinations include combining
anti-PD-1 antibody with recombinant IL-2 or recombinant IFN.alpha.2
for the treatment of melanoma or renal cell carcinoma. Recombinant
IL-2 enhances T cell outgrowth in cancer patients. Recombinant
IFN.alpha.2 inhibits cancer cell growth but also increases
expression of the inhibitory ligands for PD-1 on cancer cells,
antigen-presenting cells and other somatic cells in the treated
patients. Anti-PD-1 can be combined with other cytokines that might
be considered useful for the treatment of cancer or infectious
diseases.
[0065] In some embodiments, anti-PD-1 antibodies or antibody
fragments can be combined with a vaccine to prevent or treat cancer
or infectious disease. As a non-limiting example, anti-PD-1 could
be combined with a protein, peptide or DNA vaccine containing one
or more antigens which are relevant to the cancer or infection to
be treated, or a vaccine comprising of dendritic cells pulsed with
such a) antigen. Another embodiment includes the use of anti-PD-1
with (attenuated) cancer cell or whole virus vaccines. One
embodiment involves a combination of anti-PD-1 therapy with a whole
cell cancer vaccine that is engineered to secrete GM-CSF.
[0066] In some embodiments, anti-PD-1 antibodies or antibody
fragments can be combined with treatment that is considered to be
standard of care in cancer or infectious disease. Rationale for
such combinations is that concurrent increased immune activation by
anti-PD-1 will induce or facilitate initial clinical response to
standard of care treatment, induce durable clinical response and
long-term immune control of disease.
[0067] In one embodiment, treatment with anti-PD-1 antibodies or
antibody fragments may be combined with chemotherapy. Chemotherapy
using cytotoxic agents will result in cancer cell death thereby
increasing release of tumor antigens. Such increased availability
of tumor antigen may result in synergy with anti-PD-1 treatment. A
non-limiting example is provided by the use of decarbazine or
temozolomide for the treatment of melanoma and gemcitabine for
pancreatic cancer.
[0068] In one embodiment, treatment with anti-PD-1 antibodies or
antibody fragments may be combined with radiotherapy. Radiotherapy
induces cancer cell death and increasing availability of tumor
antigens for presentation and activation of immune cells.
[0069] In another embodiment, treatment with anti-PD-1 antibodies
or antibody fragments may be combined with surgery to remove cancer
cells from a subject.
[0070] In other embodiments, anti-PD-1 antibodies or antibody
fragments may be combined with therapies which may result in
synergy with PD-1 blockade including targeted agents used for
hormone deprivation or inhibition of angiogenesis, or targeting
proteins active in tumor cells, all resulting in enhanced tumor
cell death and availability of immune stimulating tumor antigens.
In combination with an anti-PD-1 antibody or antibody fragment,
increased T cell activation may result in durable immune control of
cancer.
[0071] In some embodiments, an anti-PD-1 antibody or antibody
fragment may be combined with another therapeutic antibody useful
for the treatment of cancer or infectious disease. A non-limiting
example is provided by the combination of anti-PD-1 with an
antibody targeting Her2/neu or targeting the EGF receptor. In
another non-limiting example, an anti-PD-1 antibody or antibody
fragment is combined with treatment targeting VEGF or its
receptors. In another embodiment, an anti-PD-1 antibody or antibody
fragment is combined with anti-CTLA-4. In yet another nonlimiting
example, anti-PD-1 is combined with an antibody that targets
RSV.
BRIEF DESCRIPTION OF THE DRAWINGS
[0072] FIGS. 1A and 1B show the results of experiments
demonstrating that antibodies immobilized from hybridoma
supematants are able to reduce IL-2 secretion by Jurkat E6.2.11
cells stimulated with immobilized anti-CD3 and soluble
anti-CD28.
[0073] FIGS. 2A and 2B show the results of experiments
demonstrating that antibodies against human PD-1 bind to PD-1. FIG.
2A is a graph showing dose dependent binding of anti-PD-1
antibodies to purified PD-1/Fc in a protein ELISA. FIG. 2B is a
graph showing dose dependent binding of anti PD-1 antibodies to
PD-1 expressed on the surface of CHO cells transfected with hPD-1
in a CELISA.
[0074] FIGS. 3A and 3B show results of FMAT experiments
demonstrating that the antibodies against PD-1 compete for binding
of PD-L1 and PD-L2 to CHO cells transfected with human PD-1. FIG.
3A is a graph showing dose dependent inhibition of binding of PD-L1
by hPD-1.08A and hPD-1.09A and to a lesser extent by J116. FIG. 3B
is a graph showing dose dependent inhibition of PD-L2.
[0075] FIG. 4 is a bar graph which shows results of experiments
demonstrating that SEB-stimulated IL-2 production by healthy donor
blood cells is enhanced in the presence of anti-PD-1, anti PD-L1 or
anti-CTLA-4 antibodies. Bars show the average fold increase in IL-2
across donors (.+-.SEM). Numbers inside each bar indicate the
number of donors represented. Mouse (m)IgG1 is the isotype control
for anti-PD-1.08A (08A), anti-PD-1.09A (09A) and anti-PD-L1. Mouse
(m) IgG2a is the isotype control for anti-CTLA-4. Each IL-2 value
is compared to its own control to determine the fold change (fold
change IL-2 of 4 means 400% increase in IL-2 production when
compared to SEB alone). None=SEB alone.
[0076] FIG. 5 shows results of experiments demonstrating that
anti-PD-1 antibodies promote T cell proliferation and cytokine
secretion (IL-2 and IFN.gamma.) when stimulated with the recall
antigen tetanus toxoid. FIG. 5 shows concentration dependent
IFN.gamma. secretion. FIG. 6 is a graph depicting the k.sub.assoc
and k.sub.dissoc rates for anti-PD-1 antibodies as measured by
bio-light interferometry. Diagonal lines indicate theoretical
calculated K.sub.D values. The antibodies are listed at the right
by K.sub.D in ascending order.
[0077] FIG. 7 is a bar graph which shows results of experiments
demonstrating that SEB-stimulated IL-2 production by healthy donor
blood cells is increased in the presence of 25 ug/ml murine (09A)
or humanized anti-PD-1 antibodies (h409A11, h409A16 and h409A17).
Bars show the average fold increase in IL-2 across three donors
(+SEM). Mouse (m) IgG1 is the isotype control for anti-PD-1.09A
(09A). Human (h) IgG4 is the isotype control for h409A11, h409A16
and h409A17 antibodies. Each IL-2 value is compared to its own
control to determine the fold change. None=SEB alone.
DETAILED DESCRIPTION OF THE INVENTION
Abbreviations and Definitions
[0078] Throughout the detailed description and examples of the
invention the following abbreviations will be used: [0079]
hPD-1.08A Murine monoclonal anti-hPD-1 antibody [0080] hPD-1.09A
Murine monoclonal anti-hPD-1 antibody [0081] 08A-VH VH isolated
from hPD-1.08A hybridoma [0082] 08A-VK VK isolated from hPD-1.08A
hybridoma [0083] 09A-VH VH isolated from hPD-1.09A hybridoma [0084]
09A-VK VK isolated from hPD-1.09A hybridoma [0085] c109A Chimeric
IgG1 version of hPD1.09A antibody [0086] c109A-VH Chimeric heavy
chain, consisting of murine 09A-VH fused to hIgG1 constant region
[0087] c109A-VK Chimeric light chain, consisting of murine 09A-VK
fused to human kappa constant region [0088] 109A-H Humanized IgG1
09A heavy chain sequence with zero back mutations. [0089] 409A-H
Humanized IgG4-09A heavy chain sequence with zero FWR back
mutations [0090] K09A-L-11 Humanized 09A-kappa sequence with
framework originally having CDR1 length of 11 AAs [0091] K09A-L-16
Humanized 09A-kappa sequence with framework originally having CDR1
length of 16 AAs [0092] K09A-L-17 Humanized 09A-kappa sequence with
framework originally having CDR1 length of 17 AAs [0093] h409A11
Humanized IgG4 version of 09A antibody comprising a heavy chain
comprising the sequence of 409A-H and a light chain comprising the
sequence of K09A-L-11 [0094] h409A16 Humanized IgG4 version of 09A
antibody comprising a heavy chain comprising the sequence of 409A-H
and a light chain comprising the sequence of K09A-L-16 [0095]
h409A17 Humanized IgG4 version of 09A antibody comprising a heavy
chain comprising the sequence of 409A-H and a light chain
comprising the sequence of K09A-L-17 [0096] hPD-1 human PD-1
protein [0097] CDR Complementarity determining region in the
immunoglobulin variable regions, defined using the Kabat numbering
system [0098] EC50 concentration resulting in 50% efficacy or
binding [0099] ELISA Enzyme-linked immunosorbant assay [0100] FW
Antibody framework region: the immunoglobulin variable regions
excluding the CDR regions [0101] HRP Horseradish peroxidase [0102]
IL-2 interleukin 2 [0103] IFN interferon [0104] IC50 concentration
resulting in 50% inhibition [0105] IgG Immunoglobulin G [0106]
Kabat An immunoglobulin alignment and numbering system pioneered by
Elvin A Kabat [0107] mAb Monoclonal antibody [0108] MES
2-(N-morpholino)ethanesulfonic acid [0109] NHS Normal human serum
[0110] PCR Polymerase chain reaction [0111] SAM sheep anti-mouse
(IgG) polyclonal antibody [0112] V region The segment of IgG chains
which is variable in sequence between different antibodies. It
extends to Kabat residue 109 in the light chain and 113 in the
heavy chain. [0113] VH Immunoglobulin heavy chain variable region
[0114] VK Immunoglobulin kappa light chain variable region
[0115] "Antibody" refers to any form of antibody that exhibits the
desired biological activity, such as inhibiting binding of a ligand
to its receptor, or by inhibiting ligand-induced signaling of a
receptor. Thus, "antibody" is used in the broadest sense and
specifically covers, but is not limited to, monoclonal antibodies
(including full length monoclonal antibodies), polyclonal
antibodies, and multispecific antibodies (e.g., bispecific
antibodies).
[0116] "Antibody fragment" and "antibody binding fragment" mean
antigen-binding fragments and analogues of an antibody, typically
including at least a portion of the antigen binding or variable
regions (e.g. one or more CDRs) of the parental antibody. An
antibody fragment retains at least some of the binding specificity
of the parental antibody. Typically, an antibody fragment retains
at least 10% of the parental binding activity when that activity is
expressed on a molar basis. Preferably, an antibody fragment
retains at least 20%, 50%, 70%, 80%, 90%, 95% or 100% or more of
the parental antibody's binding affinity for the target. Examples
of antibody fragments include, but are not limited to, Fab, Fab',
F(ab')2, and Fv fragments; diabodies; linear antibodies;
single-chain antibody molecules, e.g., sc-Fv, unibodies (technology
from Genmab); nanobodies (technology from Domantis); domain
antibodies (technology from Ablynx); and multispecific antibodies
formed from antibody fragments. Engineered antibody variants are
reviewed in Holliger and Hudson (2005) Nat. Biotechnol.
23:1126-1136.
[0117] A "Fab fragment" is comprised of one light chain and the
C.sub.H1 and variable regions of one heavy chain. The heavy chain
of a Fab molecule cannot form a disulfide bond with another heavy
chain molecule.
[0118] An "Fc" region contains two heavy chain fragments comprising
the C.sub.H1 and C.sub.H.sup.2 domains of an antibody. The two
heavy chain fragments are held together by two or more disulfide
bonds and by hydrophobic interactions of the CH3 domains.
[0119] A "Fab' fragment" contains one light chain and a portion of
one heavy chain that contains the V.sub.H domain and the C H1
domain and also the region between the C.sub.H1 and C.sub.H.sup.2
domains, such that an interchain disulfide bond can be formed
between the two heavy chains of two Fab' fragments to form a
F(ab').sub.2 molecule.
[0120] A "F(ab').sub.2 fragment" contains two light chains and two
heavy chains containing a portion of the constant region between
the C.sub.H1 and C.sub.H.sup.2 domains, such that an interchain
disulfide bond is formed between the two heavy chains. A
F(ab').sub.2 fragment thus is composed of two Fab' fragments that
are held together by a disulfide bond between the two heavy
chains.
[0121] The "Fv region" comprises the variable regions from both the
heavy and light chains, but lacks the constant regions.
[0122] A "single-chain Fv antibody" (or "scFv antibody") refers to
antibody fragments comprising the V.sub.H and V.sub.L domains of an
antibody, wherein these domains are present in a single polypeptide
chain. Generally, the Fv polypeptide further comprises a
polypeptide linker between the V.sub.H and V.sub.L domains which
enables the scFv to form the desired structure for antigen binding.
For a review of scFv, see Pluckthun (1994) THE PHARMACOLOGY OF
MONOCLONAL ANTIBODIES, vol. 113, Rosenburg and Moore eds.
Springer-Verlag, New York, pp. 269-315. See also, International
Patent Application Publication No. WO 88/01649 and U.S. Pat. Nos.
4,946,778 and 5,260,203.
[0123] A "diabody" is a small antibody fragment with two
antigen-binding sites. The fragments comprises a heavy chain
variable domain (V.sub.H) connected to a light chain variable
domain (V.sub.L) in the same polypeptide chain (V.sub.H-V.sub.L or
V.sub.L-V.sub.H). By using a linker that is too short to allow
pairing between the two domains on the same chain, the domains are
forced to pair with the complementary domains of another chain and
create two antigen-binding sites. Diabodies are described more
fully in, e.g., EP 404,097; WO 93/11161; and Holliger et al. (1993)
Proc. Natl. Acad. Sci. USA 90: 6444-6448.
[0124] A "domain antibody fragment" is an immunologically
functional immunoglobulin fragment containing only the variable
region of a heavy chain or the variable region of a light chain. In
some instances, two or more V.sub.H regions are covalently joined
with a peptide linker to create a bivalent domain antibody
fragment. The two V.sub.H regions of a bivalent domain antibody
fragment may target the same or different antigens.
[0125] An antibody fragment of the invention may comprise a
sufficient portion of the constant region to permit dimerization
(or multimerization) of heavy chains that have reduced disulfide
linkage capability, for example where at least one of the hinge
cysteines normally involved in inter-heavy chain disulfide linkage
is altered as described herein. In another embodiment, an antibody
fragment, for example one that comprises the Fc region, retains at
least one of the biological functions normally associated with the
Fc region when present in an intact antibody, such as FcRn binding,
antibody half life modulation, ADCC function, and/or complement
binding (for example, where the antibody has a glycosylation
profile necessary for ADCC function or complement binding).
[0126] The term "chimeric" antibody refers to antibodies in which a
portion of the heavy and/or light chain is identical with or
homologous to corresponding sequences in antibodies derived from a
particular species or belonging to a particular antibody class or
subclass, while the remainder of the chain(s) is identical with or
homologous to corresponding sequences in antibodies derived from
another species or belonging to another antibody class or subclass,
as well as fragments of such antibodies, so long as they exhibit
the desired biological activity (See, for example, U.S. Pat. No.
4,816,567 and Morrison et al., 1984, Proc. Nat. Acad. Sci. USA
81:6851-6855).
[0127] "Humanized" forms of non-human (for example, murine)
antibodies are chimeric antibodies that contain minimal sequence
derived from non-human immunoglobulin. For the most part, humanized
antibodies are human immunoglobulins (recipient antibody) in which
residues from a hypervariable region of the recipient are replaced
by residues from a hypervariable region of a non-human species
(donor antibody) such as mouse, rat, rabbit or nonhuman primate
having the desired specificity, affinity, and capacity. In some
instances, Fv framework region (FR) residues of the human
immunoglobulin are replaced by corresponding non-human residues.
Furthermore, humanized antibodies may comprise residues that are
not found in the recipient antibody or in the donor antibody. These
modifications are made to further refine antibody performance. In
general, the humanized antibody will comprise substantially all of
at least one, and typically two, variable domains, in which all or
substantially all of the hypervariable loops correspond to those of
a non-human immunoglobulin and all or substantially all of the FR
regions are those of a human immunoglobulin sequence. The humanized
antibody optionally also will comprise at least a portion of an
immunoglobulin constant region (Fc), typically that of a human
immunoglobulin. For further details, see Jones et al., Nature
321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988);
and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).
[0128] The term "hypervariable region," as used herein, refers to
the amino acid residues of an antibody which are responsible for
antigen-binding. The hypervariable region comprises amino acid
residues from a "complementarity determining region" or "CDR,"
defined by sequence alignment, for example residues 24-34 (L1),
50-56 (L2) and 89-97 (L3) in the light chain variable domain and
31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable
domain; see Kabat et al., 1991, Sequences of proteins of
Immunological Interest, 5th Ed. Public Health Service, National
Institutes of Health, Bethesda, Md. and/or those residues from a
"hypervariable loop" (HVL), as defined structurally, for example,
residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain
variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the
heavy chain variable domain; see Chothia and Leskl, 1987, J. Mol.
Biol. 196:901-917. "Framework" or "FR" residues are those variable
domain residues other than the hypervariable region residues as
herein defined.
[0129] A "human antibody" is an antibody that possesses an amino
acid sequence corresponding to that of an antibody produced by a
human and/or has been made using any of the techniques for making
human antibodies disclosed herein. This definition specifically
excludes a humanized antibody that comprises non-human
antigen-binding residues.
[0130] An "isolated" antibody is one that has been identified and
separated and/or recovered from a component of its natural
environment. Contaminant components of its natural environment are
materials that would interfere with diagnostic or therapeutic uses
for the antibody, and may include enzymes, hormones, and other
proteinaceous or nonproteinaceous solutes. In some embodiments, the
antibody will be purified (1) to greater than 95% by weight of
antibody as determined by the Lowry method, and most preferably
more than 99% by weight, (2) to a degree sufficient to obtain at
least 15 residues of N-terminal or internal amino acid sequence by
use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE
under reducing or nonreducing conditions using Coomassie blue or,
preferably, silver stain. Isolated antibody includes the antibody
in situ within recombinant cells since at least one component of
the antibody's natural environment will not be present. Ordinarily,
however, isolated antibody will be prepared by at least one
purification step.
[0131] An "isolated" nucleic acid molecule is a nucleic acid
molecule that is identified and separated from at least one
contaminant nucleic acid molecule with which it is ordinarily
associated in the natural source of the antibody nucleic acid. An
isolated nucleic acid molecule is other than in the form or setting
in which it is found in nature. Isolated nucleic acid molecules
therefore are distinguished from the nucleic acid molecule as it
exists in natural cells. However, an isolated nucleic acid molecule
includes a nucleic acid molecule contained in cells that ordinarily
express the antibody where, for example, the nucleic acid molecule
is in a chromosomal location different from that of natural
cells.
[0132] The term "monoclonal antibody" as used herein refers to an
antibody obtained from a population of substantially homogeneous
antibodies, i.e., the individual antibodies comprising the
population are identical except for possible naturally occurring
mutations that may be present in minor amounts. Monoclonal
antibodies are highly specific, being directed against a single
antigenic site. Furthermore, in contrast to conventional
(polyclonal) antibody preparations that typically include different
antibodies directed against different determinants (epitopes), each
monoclonal antibody is directed against a single determinant on the
antigen. The modifier "monoclonal" indicates the character of the
antibody as being obtained from a substantially homogeneous
population of antibodies, and is not to be construed as requiring
production of the antibody by any particular method. For example,
the monoclonal antibodies to be used in accordance with the present
invention may be made by the hybridoma method first described by
Kohler et al., 1975, Nature 256:495, or may be made by recombinant
DNA methods (see, for example, U.S. Pat. No. 4,816,567). The
"monoclonal antibodies" may also be isolated from phage antibody
libraries using the techniques described in Clackson et al., 1991,
Nature 352:624-628 and Marks et al., 1991, J Mol. Biol.
222:581-597, for example. The monoclonal antibodies herein
specifically include "chimeric" antibodies.
[0133] As used herein, the term "immune cell" includes cells that
are of hematopoietic origin and that play a role in the immune
response. Immune cells include lymphocytes, such as B cells and T
cells; natural killer cells; myeloid cells, such as monocytes,
macrophages, eosinophils, mast cells, basophils, and
granulocytes.
[0134] As used herein, an "immunoconjugate" refers to an anti-PD-1
antibody, or a fragment thereof, conjugated to a therapeutic
moiety, such as a bacterial toxin, a cytotoxic drug or a
radiotoxin. Toxic moieties can be conjugated to antibodies of the
invention using methods available in the art.
[0135] The following nucleic acid ambiguity codes are used herein:
R=A or G; Y=C or T; M=A or C; K=G or T; S=G or C; and W=A or T.
[0136] As used herein, a sequence "variant" refers to a sequence
that differs from the disclosed sequence at one or more amino acid
residues but which retains the biological activity of the resulting
molecule.
[0137] "Conservatively modified variants" or "conservative amino
acid substitution" refers to substitutions of amino acids are known
to those of skill in this art and may be made generally without
altering the biological activity of the resulting molecule. Those
of skill in this art recognize that, in general, single amino acid
substitutions in non-essential regions of a polypeptide do not
substantially alter biological activity (see, e.g., Watson, et al.,
Molecular Biology of the Gene, The Benjamin/Cummings Pub. Co., p.
224 (4th Edition 1987)). Such exemplary substitutions are
preferably made in accordance with those set forth below as
follows:
Exemplary Conservative Amino Acid Substitutions
TABLE-US-00001 [0138] Original residue Conservative substitution
Ala (A) Gly; Ser Arg (R) Lys, His Asn (N) Gln; His Asp (D) Glu; Asn
Cys (C) Ser; Ala Gln (Q) Asn Glu (E) Asp; Gln Gly (G) Ala His (H)
Asn; Gln Ile (I) Leu; Val Leu (L) Ile; Val Lys (K) Arg; His Met (M)
Leu; Ile; Tyr Phe (F) Tyr; Met; Leu Pro (P) Ala Ser (S) Thr Thr (T)
Ser Trp (W) Tyr; Phe Tyr (Y) Trp; Phe Val (V) Ile; Leu
[0139] As used herein, "% identity" between two sequences refers to
a function of the number of identical positions shared by the
sequences (i.e., % homology=# of identical positions/total # of
positions .times.100), taking into account the number of gaps, and
the length of each gap, which need to be introduced for optimal
alignment of the two sequences. The comparison of sequences and
determination of percent identity between two sequences can be
accomplished using a mathematical algorithm. For example, the
percent identity between two amino acid sequences can be determined
using the algorithm of E. Meyers and W. Miller (Comput. Appl.
Biosci., 4:11-17 (1988)) which has been incorporated into the ALIGN
program (version 2.0), using a PAM120 weight residue table, a gap
length penalty of 12 and a gap penalty of 4. In addition, the
percent identity between two amino acid sequences can be determined
using the Needleman and Wunsch (J. MoI. Biol. 48:444-453 (1970))
algorithm which has been incorporated into the GAP program in the
GCG software package (available at www.gcg.com), using either a
Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14,
12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
[0140] As used herein, the term "about" refers to a value that is
within an acceptable error range for the particular value as
determined by one of ordinary skill in the art, which will depend
in part on how the value is measured or determined, i.e., the
limitations of the measurement system. For example, "about" can
mean within 1 or more than 1 standard deviation per the practice in
the art. Alternatively, "about" or "comprising essentially of" can
mean a range of up to 20%. Furthermore, particularly with respect
to biological systems or processes, the terms can mean up to an
order of magnitude or up to 5-fold of a value. When particular
values are provided in the application and claims, unless otherwise
stated, the meaning of "about" or "comprising essentially of"
should be assumed to be within an acceptable error range for that
particular value.
[0141] "Specifically" binds, when referring to a ligand/receptor,
antibody/antigen, or other binding pair, indicates a binding
reaction which is determinative of the presence of the protein,
e.g., PD-1, in a heterogeneous population of proteins and/or other
biologics. Thus, under designated conditions, a specified
ligand/antigen binds to a particular receptor/antibody and does not
bind in a significant amount to other proteins present in the
sample.
[0142] "Administration" and "treatment," as it applies to an
animal, human, experimental subject, cell, tissue, organ, or
biological fluid, refers to contact of an exogenous pharmaceutical,
therapeutic, diagnostic agent, or composition to the animal, human,
subject, cell, tissue, organ, or biological fluid. "Administration"
and "treatment" can refer, e.g., to therapeutic, pharmacokinetic,
diagnostic, research, and experimental methods. Treatment of a cell
encompasses contact of a reagent to the cell, as well as contact of
a reagent to a fluid, where the fluid is in contact with the cell.
"Administration" and "treatment" also means in vitro and ex vivo
treatments, e.g., of a cell, by a reagent, diagnostic, binding
composition, or by another cell.
[0143] "Effective amount" encompasses an amount sufficient to
ameliorate or prevent a symptom or sign of the medical condition.
Effective amount also means an amount sufficient to allow or
facilitate diagnosis. An effective amount for a particular subject
may vary depending on factors such as the condition being treated,
the overall health of the patient, the method route and dose of
administration and the severity of side affects. An effective
amount can be the maximal dose or dosing protocol that avoids
significant side effects or toxic effects. The effect will result
in an improvement of a diagnostic measure or parameter by at least
5%, usually by at least 10%, more usually at least 20%, most
usually at least 30%, preferably at least 40%, more preferably at
least 50%, most preferably at least 60%, ideally at least 70%, more
ideally at least 80%, and most ideally at least 90%, where 100% is
defined as the diagnostic parameter shown by a normal subject (see,
e.g., Maynard, et al. (1996) A Handbook of SOPs for Good Clinical
Practice, Interpharm Press, Boca Raton, Fla.; Dent (2001) Good
Laboratory and Good Clinical Practice, Urch Publ., London, UK).
Monoclonal Antibodies
[0144] Monoclonal antibodies to PD-1 can be made according to
knowledge and skill in the art of injecting test subjects with PD-1
antigen and then isolating hybridomas expressing antibodies having
the desired sequence or functional characteristics.
[0145] DNA encoding the monoclonal antibodies is readily isolated
and sequenced using conventional procedures (e.g., by using
oligonucleotide probes that are capable of binding specifically to
genes encoding the heavy and light chains of the monoclonal
antibodies). The hybridoma cells serve as a preferred source of
such DNA. Once isolated, the DNA may be placed into expression
vectors, which are then transfected into host cells such as E. coli
cells, simian COS cells, Chinese hamster ovary (CHO) cells, or
myeloma cells that do not otherwise produce immunoglobulin protein,
to obtain the synthesis of monoclonal antibodies in the recombinant
host cells. Recombinant production of antibodies will be described
in more detail below.
[0146] In a further embodiment, antibodies or antibody fragments
can be isolated from antibody phage libraries generated using the
techniques described in McCafferty et al., 1990, Nature,
348:552-554. Clackson et al., 1991, Nature, 352:624-628, and Marks
et al., 1991, J. Mol. Biol. 222:581-597 describe the isolation of
murine and human antibodies, respectively, using phage libraries.
Subsequent publications describe the production of high affinity
(nM range) human antibodies by chain shuffling (Marks et al., 1992,
Bio/Technology, 10:779-783), as well as combinatorial infection and
in vivo recombination as a strategy for constructing very large
phage libraries (Waterhouse et al., 1993, Nuc. Acids. Res.
21:2265-2266). Thus, these techniques are viable alternatives to
traditional monoclonal antibody hybridoma techniques for isolation
of monoclonal antibodies.
Chimeric Antibodies
[0147] The antibody DNA also may be modified, for example, by
substituting the coding sequence for human heavy- and light-chain
constant domains in place of the homologous murine sequences (U.S.
Pat. No. 4,816,567; Morrison, et al., 1984, Proc. Natl Acad. Sci.
USA, 81:6851), or by covalently joining to the immunoglobulin
coding sequence all or part of the coding sequence for
non-immunoglobulin material (e.g., protein domains). Typically such
non-immunoglobulin material is substituted for the constant domains
of an antibody, or is substituted for the variable domains of one
antigen-combining site of an antibody to create a chimeric bivalent
antibody comprising one antigen-combining site having specificity
for an antigen and another antigen-combining site having
specificity for a different antigen.
Humanized and Human Antibodies
[0148] A humanized antibody has one or more amino acid residues
from a source that is non-human. The non-human amino acid residues
are often referred to as "import" residues, and are typically taken
from an "import" variable domain. Humanization can be performed
generally following the method of Winter and co-workers (Jones et
al., 1986, Nature 321:522-525; Riechmann et al., 1988, Nature,
332:323-327; Verhoeyen et al., 1988, Science 239:1534-1536), by
substituting rodent CDRs or CDR sequences for the corresponding
sequences of a human antibody. Accordingly, such "humanized"
antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567)
wherein substantially less than an intact human variable domain has
been substituted by the corresponding sequence from a non-human
species. In practice, humanized antibodies are typically human
antibodies in which some CDR residues and possibly some FR residues
are substituted by residues from analogous sites in non-human, for
example, rodent antibodies.
[0149] The choice of human variable domains, both light and heavy,
to be used in making the humanized antibodies is very important to
reduce antigenicity. According to the so-called "best-fit" method,
the sequence of the variable domain of a rodent antibody is
screened against the entire library of known human variable-domain
sequences. The human sequence which is closest to that of the
rodent is then accepted as the human framework (FR) for the
humanized antibody (Sims et al., 1987, J. Immunol. 151:2296;
Chothia et al., 1987, J. Mol. Biol. 196:901). Another method uses a
particular framework derived from the consensus sequence of all
human antibodies of a particular subgroup of light or heavy chains.
The same framework may be used for several different humanized
antibodies (Carter et al., 1992, Proc. Natl. Acad. Sci. USA
89:4285; Presta et al., 1993, J. Immnol. 151:2623).
[0150] It is further important that antibodies be humanized with
retention of high affinity for the antigen and other favorable
biological properties. To achieve this goal, according to a
preferred method, humanized antibodies are prepared by a process of
analysis of the parental sequences and various conceptual humanized
products using three-dimensional models of the parental and
humanized sequences. Three-dimensional immunoglobulin models are
commonly available and are familiar to those skilled in the art.
Computer programs are available which illustrate and display
probable three-dimensional conformational structures of selected
candidate immunoglobulin sequences. Inspection of these displays
permits analysis of the likely role of the residues in the
functioning of the candidate immunoglobulin sequence, i.e., the
analysis of residues that influence the ability of the candidate
immunoglobulin to bind its antigen. In this way, FR residues can be
selected and combined from the recipient and import sequences so
that the desired antibody characteristic, such as increased
affinity for the target antigen(s), is achieved. In general, the
CDR residues are directly and most substantially involved in
influencing antigen binding.
[0151] Humanization of antibodies is a straightforward protein
engineering task. Nearly all murine antibodies can be humanized by
CDR grafting, resulting in the retention of antigen binding. See,
Lo, Benny, K. C., editor, in Antibody Engineering: Methods and
Protocols, volume 248, Humana Press, New Jersey, 2004.
[0152] Alternatively, it is now possible to produce transgenic
animals (e.g., mice) that are capable, upon immunization, of
producing a full repertoire of human antibodies in the absence of
endogenous immunoglobulin production. For example, it has been
described that the homozygous deletion of the antibody heavy-chain
joining region (JH) gene in chimeric and germ-line mutant mice
results in complete inhibition of endogenous antibody production.
Transfer of the human germ-line immunoglobulin gene array in such
germ-line mutant mice will result in the production of human
antibodies upon antigen challenge. See, e.g., Jakobovits et al.,
1993, Proc. Natl. Acad. Sci. USA 90:2551; Jakobovits et al., 1993,
Nature 362:255-258; Bruggermann et al., 1993, Year in Immunology
7:33; and Duchosal et al., 1992, Nature 355:258. Human antibodies
can also be derived from phage-display libraries (Hoogenboom et
al., 1991, J. Mol. Biol. 227:381; Marks et al., J Mol. Biol. 1991,
222:581-597; Vaughan et al., 1996, Nature Biotech 14:309).
Antibody Purification
[0153] When using recombinant techniques, the antibody can be
produced intracellularly, in the periplasmic space, or directly
secreted into the medium. If the antibody is produced
intracellularly, as a first step, the particulate debris, either
host cells or lysed fragments, is removed, for example, by
centrifugation or ultrafiltration. Carter et al., 1992, Bio
Technology 10:163-167 describe a procedure for isolating antibodies
which are secreted to the periplasmic space of E. coli. Briefly,
cell paste is thawed in the presence of sodium acetate (pH 3.5),
EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min.
Cell debris can be removed by centrifugation. Where the antibody is
secreted into the medium, supernatants from such expression systems
are generally first concentrated using a commercially available
protein concentration filter, for example, an Amicon or Millipore
Pellicon ultrafiltration unit. A protease inhibitor such as PMSF
may be included in any of the foregoing steps to inhibit
proteolysis and antibiotics may be included to prevent the growth
of adventitious contaminants.
[0154] The antibody composition prepared from the cells can be
purified using, for example, hydroxylapatite chromatography, gel
electrophoresis, dialysis, and affinity chromatography, with
affinity chromatography being the preferred purification technique.
The suitability of protein A as an affinity ligand depends on the
species and isotype of any immunoglobulin Fc region that is present
in the antibody. Protein A can be used to purify antibodies that
are based on human .gamma.1, .gamma.2, or .gamma.4 heavy chains
(Lindmark et al., 1983, J. Immunol. Meth. 62:1-13). Protein G is
recommended for all mouse isotypes and for human .gamma.3 (Guss et
al., 1986, EMBO J 5:15671575). The matrix to which the affinity
ligand is attached is most often agarose, but other matrices are
available. Mechanically stable matrices such as controlled pore
glass or poly(styrenedivinyl)benzene allow for faster flow rates
and shorter processing times than can be achieved with agarose.
Where the antibody comprises a CH3 domain, the Bakerbond ABX.TM.
resin (J. T. Baker, Phillipsburg, N.J.) is useful for purification.
Other techniques for protein purification such as fractionation on
an ion-exchange column, ethanol precipitation, Reverse Phase HPLC,
chromatography on silica, chromatography on heparin SEPHAROSE.TM.
chromatography on an anion or cation exchange resin (such as a
polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium
sulfate precipitation are also available depending on the antibody
to be recovered.
[0155] In one embodiment, the glycoprotein may be purified using
adsorption onto a lectin substrate (e.g. a lectin affinity column)
to remove fucose-containing glycoprotein from the preparation and
thereby enrich for fucose-free glycoprotein.
Pharmaceutical Formulations
[0156] The invention comprises pharmaceutical formulations of a
PD-1 antibody or antibody fragment of the invention. To prepare
pharmaceutical or sterile compositions, the antibody or fragment
thereof is admixed with a pharmaceutically acceptable carrier or
excipient, see, e.g., Remington's Pharmaceutical Sciences and U.S.
Pharmacopeia: National Formulary, Mack Publishing Company, Easton,
Pa. (1984). Formulations of therapeutic and diagnostic agents may
be prepared by mixing with physiologically acceptable carriers,
excipients, or stabilizers in the form of, e.g., lyophilized
powders, slurries, aqueous solutions or suspensions (see, e.g.,
Hardman, et al. (2001) Goodman and Gilman's The Pharmacological
Basis of Therapeutics, McGraw-Hill, New York, N.Y.; Gennaro (2000)
Remington: The Science and Practice of Pharmacy, Lippincott,
Williams, and Wilkins, New York, N.Y.; Avis, et al. (eds.) (1993)
Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker,
NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms:
Tablets, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990)
Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, NY;
Weiner and Kotkoskie (2000) Excipient Toxicity and Safety, Marcel
Dekker, Inc., New York, N.Y.).
[0157] Toxicity and therapeutic efficacy of the antibody
compositions, administered alone or in combination with an
immunosuppressive agent, can be determined by standard
pharmaceutical procedures in cell cultures or experimental animals,
e.g., for determining the LD.sub.50 (the dose lethal to 50% of the
population) and the ED.sub.50 (the dose therapeutically effective
in 50% of the population). The dose ratio between toxic and
therapeutic effects is the therapeutic index and it can be
expressed as the ratio between LD.sub.50 and ED.sub.50. The data
obtained from these cell culture assays and animal studies can be
used in formulating a range of dosage for use in humans. The dosage
of such compounds lies preferably within a range of circulating
concentrations that include the ED.sub.50 with little or no
toxicity. The dosage may vary within this range depending upon the
dosage form employed and the route of administration utilized.
[0158] Suitable routes of administration include parenteral
administration, such as intramuscular, intravenous, or subcutaneous
administration and oral administration. Administration of antibody
used in the pharmaceutical composition or to practice the method of
the present invention can be carried out in a variety of
conventional ways, such as oral ingestion, inhalation, topical
application or cutaneous, subcutaneous, intraperitoneal,
parenteral, intraarterial or intravenous injection. In one
embodiment, the binding compound of the invention is administered
intravenously. In another embodiment, the binding compound of the
invention is administered subcutaneously.
[0159] Alternately, one may administer the antibody in a local
rather than systemic manner, for example, via injection of the
antibody directly into the site of action, often in a depot or
sustained release formulation. Furthermore, one may administer the
antibody in a targeted drug delivery system.
[0160] Guidance in selecting appropriate doses of antibodies,
cytokines, and small molecules are available (see, e.g.,
Wawrzynczak (1996) Antibody Therapy, Bios Scientific Pub. Ltd,
Oxfordshire, UK; Kresina (ed.) (1991) Monoclonal Antibodies,
Cytokines and Arthritis, Marcel Dekker, New York, N.Y.; Bach (ed.)
(1993) Monoclonal Antibodies and Peptide Therapy in Autoimmune
Diseases, Marcel Dekker, New York, N.Y.; Baert, et al. (2003) New
Engl. J. Med. 348:601-608; Milgrom, et al. (1999) New Engl. J. Med.
341:1966-1973; Slamon, et al. (2001) New Engl. J. Med. 344:783-792;
Beniaminovitz, et al. (2000) New Engl. J. Med. 342:613-619; Ghosh,
et al. (2003) New Engl. J. Med. 348:24-32; Lipsky, et al. (2000)
New Engl. J. Med. 343:1594-1602).
[0161] Determination of the appropriate dose is made by the
clinician, e.g., using parameters or factors known or suspected in
the art to affect treatment or predicted to affect treatment.
Generally, the dose begins with an amount somewhat less than the
optimum dose and it is increased by small increments thereafter
until the desired or optimum effect is achieved relative to any
negative side effects. Important diagnostic measures include those
of symptoms of, e.g., the inflammation or level of inflammatory
cytokines produced.
[0162] Antibodies, antibody fragments, and cytokines can be
provided by continuous infusion, or by doses at intervals of, e.g.,
one day, one week, or 1-7 times per week. Doses may be provided
intravenously, subcutaneously, intraperitoneally, cutaneously,
topically, orally, nasally, rectally, intramuscular,
intracerebrally, intraspinally, or by inhalation. A preferred dose
protocol is one involving the maximal dose or dose frequency that
avoids significant undesirable side effects. A total weekly dose is
generally at least 0.05 .mu.g/kg body weight, more generally at
least 0.2 .mu.g/kg, most generally at least 0.5 .mu.g/kg, typically
at least 1 .mu.g/kg, more typically at least 10 .mu.g/kg, most
typically at least 100 .mu.g/kg, preferably at least 0.2 mg/kg,
more preferably at least 1.0 mg/kg, most preferably at least 2.0
mg/kg, optimally at least 10 mg/kg, more optimally at least 25
mg/kg, and most optimally at least 50 mg/kg (see, e.g., Yang, et
al. (2003) New Engl. J Med. 349:427-434; Herold, et al. (2002) New
Engl. J Med. 346:1692-1698; Liu, et al. (1999) J Neurol. Neurosurg.
Psych. 67:451-456; Portielji, et al. (20003) Cancer Immunol.
Immunother. 52:133-144). The desired dose of a small molecule
therapeutic, e.g., a peptide mimetic, natural product, or organic
chemical, is about the same as for an antibody or polypeptide, on a
moles/kg basis.
[0163] As used herein, "inhibit" or "treat" or "treatment" includes
a postponement of development of the symptoms associated with
disease and/or a reduction in the severity of such symptoms that
will or are expected to develop with said disease. The terms
further include ameliorating existing symptoms, preventing
additional symptoms, and ameliorating or preventing the underlying
causes of such symptoms. Thus, the terms denote that a beneficial
result has been conferred on a vertebrate subject with a
disease.
[0164] As used herein, the term "therapeutically effective amount"
or "effective amount" refers to an amount of an anti-PD-1 antibody
or fragment thereof, that when administered alone or in combination
with an additional therapeutic agent to a cell, tissue, or subject
is effective to prevent or ameliorate the disease or condition to
be treated. A therapeutically effective dose further refers to that
amount of the compound sufficient to result in amelioration of
symptoms, e.g., treatment, healing, prevention or amelioration of
the relevant medical condition, or an increase in rate of
treatment, healing, prevention or amelioration of such conditions.
When applied to an individual active ingredient administered alone,
a therapeutically effective dose refers to that ingredient alone.
When applied to a combination, a therapeutically effective dose
refers to combined amounts of the active ingredients that result in
the therapeutic effect, whether administered in combination,
serially or simultaneously. An effective amount of therapeutic will
decrease the symptoms typically by at least 10%; usually by at
least 20%; preferably at least about 30%; more preferably at least
40%, and most preferably by at least 50%.
[0165] Methods for co-administration or treatment with a second
therapeutic agent are well known in the art, see, e.g., Hardman, et
al. (eds.) (2001) Goodman and Gilman's The Pharmacological Basis of
Therapeutics, 10.sup.th ed., McGraw-Hill, New York, N.Y.; Poole and
Peterson (eds.) (2001) Pharmacotherapeutics for Advanced Practice:
A Practical Approach, Lippincott, Williams & Wilkins, Phila.,
Pa.; Chabner and Longo (eds.) (2001) Cancer Chemotherapy and
Biotherapy, Lippincott, Williams & Wilkins, Phila., Pa.
[0166] The pharmaceutical composition of the invention may also
contain other agent, including but not limited to a cytotoxic,
cytostatic, anti-angiogenic or antimetabolite agent, a tumor
targeted agent, an immune stimulating or immune modulating agent or
an antibody conjugated to a cytotoxic, cytostatic, or otherwise
toxic agent. The pharmaceutical composition can also be employed
with other therapeutic modalities such as surgery, chemotherapy and
radiation.
[0167] Typical veterinary, experimental, or research subjects
include monkeys, dogs, cats, rats, mice, rabbits, guinea pigs,
horses, and humans.
Therapeutic Uses for the Antibody and Antibody Fragments of the
Invention
[0168] The antibody or antigen binding fragments of the invention,
which specifically bind to human PD-1, can be used to increase,
enhance, stimulate or up-regulate an immune response. The
antibodies and antibody fragments of the invention are particularly
suitable for treating subjects having a disorder that can be
treated by increasing the T-cell mediated immune response.
Preferred subjects include human patients in need of enhancement of
an immune response.
Cancer
[0169] The antibody or antigen binding fragments of the invention
can be used to treat cancer (i.e., to inhibit the growth or
survival of tumor cells). Preferred cancers whose growth may be
inhibited using the antibodies of the invention include cancers
typically responsive to immunotherapy, but also cancers that have
not hitherto been associated with immunotherapy. Non-limiting
examples of preferred cancers for treatment include melanoma (e.g.,
metastatic malignant melanoma), renal cancer (e.g. clear cell
carcinoma), prostate cancer (e.g. hormone refractory prostate
adenocarcinoma), pancreatic adenocarcinoma, breast cancer, colon
cancer, lung cancer (e.g. non-small cell lung cancer), esophageal
cancer, squamous cell carcinoma of the head and neck, liver cancer,
ovarian cancer, cervical cancer, thyroid cancer, glioblastoma,
glioma, leukemia, lymphoma, and other neoplastic malignancies.
Additionally, the invention includes refractory or recurrent
malignancies whose growth may be inhibited using the antibodies of
the invention.
[0170] The antibody or antibody fragments of the invention can be
used alone or in combination with: other anti-neoplastic agents or
immunogenic agents (for example, attenuated cancerous cells, tumor
antigens (including recombinant proteins, peptides, and
carbohydrate molecules), antigen presenting cells such as dendritic
cells pulsed with tumor derived antigen or nucleic acids, immune
stimulating cytokines (for example, IL-2, IFNa2, GM-CSF), and cells
transfected with genes encoding immune stimulating cytokines such
as but not limited to GM-CSF); standard cancer treatments (for
example, chemotherapy, radiotherapy or surgery); or other
antibodies (including but not limited to antibodies to VEGF, EGFR,
Her2/neu, VEGF receptors, other growth factor receptors, CD20,
CD40, CTLA-4, OX-40, 4-IBB, and ICOS).
Infectious Diseases
[0171] The antibody or antibody fragments of the invention can also
be used to prevent or treat infections and infectious disease. The
antibody or antibody fragments can be used alone, or in combination
with vaccines, to stimulate the immune response to pathogens,
toxins, and self-antigens. The antibodies or antigen-binding
fragment thereof can be used to stimulate immune response to
viruses infectious to humans, such as, but not limited to, human
immunodeficiency viruses, hepatitis viruses class A, B and C,
Epstein Barr virus, human cytomegalovirus, human papilloma viruses,
herpes viruses. The antibodies or antigen-binding fragment thereof
can be used to stimulate immune response to infection with
bacterial or fungal parasites, and other pathogens.
Vaccination Adjuvant
[0172] The antibody or antibody fragments of the invention can be
used in conjunction with other recombinant proteins and/or peptides
(such as tumor antigens or cancer cells) in order to increase an
immune response to these proteins (i.e., in a vaccination
protocol).
[0173] For example, anti-PD-1 antibodies and antibody fragments
thereof may be used to stimulate antigen-specific immune responses
by coadministration of an anti-PD-1 antibody with an antigen of
interest (e.g., a vaccine). Accordingly, in another aspect the
invention provides a method of enhancing an immune response to an
antigen in a subject, comprising administering to the subject: (i)
the antigen; and (ii) an anti-PD-1 antibody of the invention or
antigen-binding portion thereof, such that an immune response to
the antigen in the subject is enhanced. The antigen can be, for
example, a tumor antigen, a viral antigen, a bacterial antigen or
an antigen from a pathogen. Non-limiting examples of such antigens
include, without limitation, tumor antigens, or antigens from the
viruses, bacteria or other pathogens.
Th2 Mediated Diseases
[0174] Anti-PD-1 antibodies and antibody fragments of the invention
can also be used to treat Th2 mediated diseases, such as asthma and
allergy. This is based on the finding that the antibodies of the
invention can help induce a Th1 response. Thus, the antibodies of
the invention can be used to in Th2 mediated diseases to generate a
more balanced immune response.
Ex-Vivo Activation of T Cells
[0175] The antibodies and antigen fragments of the invention can
also be used for the ex vivo activation and expansion of antigen
specific T cells and adoptive transfer of these cells into
recipients in order to increase antigen-specific T cells against
tumor. These methods may also be used to activate T cell responses
to infectious agents such as CMV. Ex vivo activation in the
presence of anti-PD-1 antibodies may be expected to increase the
frequency and activity of the adoptively transferred T cells.
Other Combination Therapies
[0176] As previously described, anti-PD-1 antibodies of the
invention can be coadministered with one or other more therapeutic
agents, e.g., a cytotoxic agent, a radiotoxic agent or an
immunosuppressive agent. The antibody can be linked to the agent
(as an immunocomplex) or can be administered separately from the
agent. In the latter case (separate administration), the antibody
can be administered before, after or concurrently with the agent or
can be co-administered with other known therapies.
[0177] Antibodies and antigen binding fragments of the invention
can also be used to increase the effectiveness of donor engrafted
tumor specific T cells.
Non-Therapeutic Uses for the Antibody and Antibody Fragments of the
Invention
[0178] A market for anti-PD-1 antibodies for non-therapeutic uses
already exists, as demonstrated by the commercial sales of J116,
and J105 monoclonal anti-hPD-1 antibodies sold by eBioscience of
San Diego, Calif., USA, for use in flow cytometric analysis,
immunohistochemistry and in vitro functional assays; and mab1086, a
monoclonal anti-hPD-1 antibody sold by R&D Systems of
Minneapolis, Minn., USA, for use in flow cytometry, Western blots
and ELISA. Antibodies of the invention may be used for any
non-therapeutic purpose now served by J116, J105 and/or
Mab1086.
[0179] The antibody of the invention may be used as an affinity
purification agent.
[0180] The antibody may also be useful in diagnostic assays, e.g.,
for detecting expression of PD-1 in specific cells, tissues, or
serum. For diagnostic applications, the antibody typically will be
labeled (either directly or indirectly) with a detectable moiety.
Numerous labels are available which can be generally grouped into
the following categories: biotin, fluorochromes, radionucleotides,
enzymes, iodine, and biosynthetic labels.
[0181] The antibody of the present invention may be employed in any
known assay method, such as competitive binding assays, direct and
indirect sandwich assays, and immunoprecipitation assays. Zola,
Monoclonal Antibodies. A Manual of Techniques, pp. 147-158 (CRC
Press, Inc. 1987).
[0182] The antibody may also be used for in vivo diagnostic assays.
Generally, the antibody is labeled with a radionuclide (such as
.sup.111In, .sup.99Tc, .sup.4C, .sup.3lI, .sup.125I, .sup.3H,
.sup.32P .sup.35S or .sup.18F) so that the antigen or cells
expressing it can be localized using immunoscintiography or
positron emission tomography.
Deposit of Materials
[0183] DNA constructs encoding the variable regions of the heavy
and light chains of the humanized antibodies h409A11, h409A16 and
h409A17 have been deposited with the American Type Culture
Collection Patent Depository (10801 University Blvd., Manassas,
Va.). The plasmid containing the DNA encoding the heavy chain of
h409A-11, h409A-16 and h409A-17 was deposited on Jun. 9, 2008 and
identified as 081469_SPD-H. The plasmid containing the DNA encoding
the light chain of h409A11 was deposited on Jun. 9, 2008 and
identified as 0801470_SPD-L-11. The plasmid containing the DNA
encoding the light chain of h409A16 was deposited on Jun. 9, 2008
and identified as 0801471_SPD-L-16. The plasmid containing the DNA
encoding the light chain of h409A17 was deposited on Jun. 9, 2008
and was designated 0801472_SPD-L-17. The deposits were made under
the provisions of the Budapest Treaty on the International
Recognition of the Deposit of Microorganisms for the Purpose of
Patent Procedure and the Regulations thereunder (Budapest
Treaty).
[0184] The foregoing written specification is considered to be
sufficient to enable one skilled in the art to practice the
invention. The present invention is not to be limited in scope by
the culture deposited, since the deposited embodiment is intended
as a single illustration of one aspect of the invention and any
culture that is functionally equivalent is within the scope of this
invention. The deposit of material herein does not constitute an
admission that the written description herein contained is
inadequate to enable the practice of any aspect of the invention,
including the best mode thereof, nor is it to be construed as
limiting the scope of the claims to the specific illustration that
it represents. Indeed, various modifications of the invention in
addition to those shown and described herein will become apparent
to those skilled in the art from the foregoing description and fall
within the scope of the appended claims.
[0185] The invention will be more fully understood by reference to
the following examples. They should not, however, be construed as
limiting the scope of this invention. All literature and patent
citations mentioned herein are expressly incorporated by
reference.
EXAMPLES
Example 1: Immunization and Selection of Anti PD-1 Antibodies
[0186] Immunization of Mice with hPD-1 cDNA
[0187] To generate antibodies against the human PD-1 (`hPD-1`)
receptor, a cDNA encoding the open reading frame of the hPD-1
receptor was obtained by PCR and subcloned into vector pcDNA3.1
(Invitrogen, Carlsbad, Calif.). Next, CHO-K1 cells were stably
transfected with hPD-1, and expression was monitored using flow
cytometry. CHO-K1 clones were isolated expressing human PD-1 on
their membranes and named CHO-hPD1.
[0188] Mice were immunized by gene gun immunization using a Helios
gene gun (BioRad) and DNA coated gold bullets (BioRad) following
manufacturers instructions. Briefly, 1 .mu.m gold particles were
coated with hPD-1 cDNA (cloned into pcDNA3.1) and, where indicated,
commercial expression vectors for mouse Flt3L and mouse GM-CSF in a
2:1:1 ratio (both from Aldevron, Fargo N. Dak.). A total of 1 .mu.g
of plasmid DNA was used to coat 500 .mu.g of gold bullets.
[0189] Specifically, 7-8 week-old female BALB/C mice were immunized
on the ear by gene gun receiving 2, 3, or 4 cycles of a shot on
both ears (see Table I). One mouse received a final booster with
5.times.10.sup.6 CHO-hPD1 cells in the peritoneal cavity.
Approximately, a 1:1000 anti-hPD-1 titers was detectable in mouse
serum after two DNA immunizations by cell ELISA using CHO-hPD-1
versus CHO-K1 parental cells. Four days after the final
immunization, mice were sacrificed, and erythrocyte-depleted spleen
cell populations were prepared as described previously
(Steenbakkers et al., 1992, J. Immunol. Meth. 152:69-77;
Steenbakkers et al., 1994, Mol. Biol. Rep. 19:125-134) and frozen
at -140.degree. C.
TABLE-US-00002 TABLE I Immunization schedule used to induce hPD-1
specific antibody titers in Balb/c mice. Week 1 Week 4 Week 7 Week
8 Week 9 Week 10 Week 11 Mouse 730 2 shots hPD1 2 shots 2 shots
Harvest of pCDNA3.1 hPD1 hPD1 spleen cells pCDNA3.1 pCDNA3.1 Mouse
731 2 shots hPD1 4 shots 5 million Harvest of pCDNA3.1 hPD1
CHO-hPD1 spleen cells pCDNA3.1 Mouse738 2 shots hPD1 2 shots 2
shots 2 shots Harvest pCDNA3.1 hPD1 hPD1 hPD1 of spleen (mFlt3L +
pCDNA3.1 pCDNA3.1 pCDNA3.1 cells mGM-CSF) (mFlt3L + (mFlt3L +
(mFlt3L + mGM-CSF) mGM-CSF) mGM-CSF)
Selection of Anti-PD-1 Antibody Producing B Cells
[0190] To select B cell clones producing anti-human-PD-1
antibodies, 2.times.10.sup.7 erythrocyte-depleted spleen cells from
hPD-1 DNA immunized mice, i.e., mouse 730, 731 and 738 (see Table
I), were pooled for a B-cell culture. Spleen cells were incubated
in DMEM/HAM's F12/10% Calf Serum (Hyclone, Logan, Utah, USA) for
one hour at 37.degree. C. in a plastic culture flask to remove
monocytes. Non-adherent cells were submitted to one round of
negative panning on CHO-K1 cells, followed by positive panning on
CHO-hPD1 cells. Both selection procedures were performed for one
hour at 37.degree. C. on confluently grown cultures in 21 cm.sup.2
petridishes or T25 culture flasks (cell cultures were irradiated
before use, to a total dose of 2000 RAD). After the positive
panning, unbound cells were removed by washing ten times with PBS
supplemented with 0.132% CaCl.sub.2.2H.sub.20 and 0.10%
MgCl.sub.2.6H.sub.20. Finally, bound B-cells were harvested by
trypsin treatment.
[0191] Selected B-cells were cultured and immortalized as described
in Steenbakkers et al., 1994, Mol. Biol. Rep. 19:125-134. Briefly,
selected B cells were mixed with 7.5% (v/v) T-cell supernatant and
50,000 irradiated (2,500 RAD) EL-4 B5 nursing cells in a final
volume of 200 .mu.L DMEM/HAM's F12/10% Bovine Calf Serum, in
96-well flat-bottomed tissue culture plates. On day eight,
supernatants were screened for their anti-hPD-1 reactivity by
CHO-hPD-1 cell ELISA using the following procedure. CHO--KI and
CHO-hPD1 cells were cultured to confluency in flatbottom 96-well
plates in 50 .mu.L DMEM/HAM'S F12, 10% FBS. Next, 50 .mu.L of
immunoglobulin-containing supernatant was added for 1 hr at
37.degree. C. After three washes with PBS-Tween, 100 .mu.L (1:1000
diluted) goat-anti-mouse-horseradish peroxidase (HRP, Southern,
Birmingham, Ala., USA) in DMEM/HAM'S F12/10% FBS was added for 1
hour at 37.degree. C. After three washes with PBS-Tween,
immobilized immunoglobulins were visualized with UPO/TMB
(Biomerieux, Boxtel, Netherlands).
[0192] From this B-cell culture, 13 hPD-1 reactive supernatants
were identified and shown to inhibit Jurkat T cell activation when
immobilized on plastic, and B-cell clones from positive wells were
immortalized by mini-electrofusion following published procedures
(Steenbakkers et al., 1992, J Immunol. Meth. 152:69-77;
Steenbakkers et al., 1994, Mol. Biol. Rep. 19:125-134).
Specifically, B-cells were mixed with 10.sup.6 NS-1 myeloma cells,
and serum was removed by washing with DMEM/HAM's F12. Next, cells
were treated with pronase solution for three minutes and
subsequently washed with fusion medium. Electrofusion was performed
in a 50 .mu.L fusion chamber by an alternating electric field of 30
s, 2 MHz, 400 V/cm followed by a square, high field pulse of 10
.mu.s, 3 kV/cm and again an alternating electric field of 30 s, 2
MHz, 400 V/cm. Finally, the content of the fusion chamber was
transferred to hybridoma selection medium and plated into a 96-well
plate under limiting dilution conditions. On day 14 after fusion,
the cultures were examined for hybridoma growth and screened for
the presence of antibody reactivity to hPD-1. This procedure
yielded five different anti-hPD-1 hybridomas, named hPD-1.05A,
hPD-1.06B, hPD-1.08A, hPD-1.09A and hPD-1.13A, that were subcloned
by limiting dilution to safeguard their integrity and further
cultured to produce antibody. Supernatants obtained from these
hybridomas strongly inhibited the IL-2 production from Jurkat
E6.2.11 cells upon anti-CD3/anti-CD28 stimulation (see FIG. 1 and
text below).
[0193] Jurkat E6.1 cells (American Type Culture Collection) were
subcloned by limiting dilution using standard methodology and
subclones were tested for enhanced capacity to produce IL-2 upon
cross-linking of CD3 and CD28. A high IL-2 producing subclone was
obtained and subsequently named Jurkat E6.2.11 and used in further
assays. Costar 3370 96-well assay plates were coated overnight at
4.degree. C. with 5 .mu.g/mL Sheep Anti-Mouse Ig (SAM). Excess of
SAM was removed and plates were blocked for 1 hr at room
temperature with 200 .mu.L/well PBS/10% Fetal Bovine Serum. After
three washes with PBS, wells were coated with 100 .mu.L/well
anti-CD3 (OKT3; 10 or 60 ng/mL) for 1 hr at 37.degree. C. After
three washes with PBS, 50 .mu.L/well PBS/10% Fetal Bovine Serum and
50 .mu.L/well B-cell- or hybridoma supernatant was added for 30 min
at 37.degree. C. After three washes with PBS, 120 .mu.L/well of
cell suspension, Jurkat E6.2.11 cells (2.times.10.sup.5
cells/well+0.5 .mu.g/mL anti-CD28 (Sanquin #M1650, Central
Laboratory for Bloodtransfusion, Amsterdam, NL) in DMEM/F12/10%
Fetal Bovine Serum) was added. After a 6 h culture, supernatant was
examined for IL-2 production using a standard sandwich ELISA with
anti-hIL-2 capture and biotinylated detection antibody pairs from
Pharmingen and Streptavidin-Horse Radish Peroxidase (Southern
Biotech) as a detection reagent. To determine the potency of these
antibodies as compared with PD-L1, a small group of mAbs was
produced on a larger scale. The mAbs were purified using Protein G
affinity chromatography (see Example 2). Purified antibodies,
hPD-L1/Fc (recombinant human B7-H1/Fc chimera, R&D systems) or
mouse IgG1 kappa (from Sigma) as a negative control were coated at
identical concentrations on plates with anti-CD3 as described
above. Jurkat E6.2.11 cells and anti-CD28 were added for six hours,
and T-cell activation was measured by IL-2 produced in the
supernatant. Two of the antibodies (hPD1.08A and hPD1.09A) showed
an 8-10 fold more potent inhibition compared to immobilized
PD-L1/Fc.
Example 2: Purification and Characterization of Murine Anti-PD-1
Antibodies
Stabilization of Anti-PD-1 Producing Hybridomas and Purification of
Anti-PD-1 Antibodies
[0194] Clonal cell populations were obtained for each of the
hybridomas by subjecting them to multiple rounds (>4) of
limiting dilution. Stable hybridoma cells were then cultured under
serum-free conditions using CELLine bioreactors
(Integra-biosciences) for six to eight days. Cells were seeded in
the inner chamber in serum-free media at a density of
3.times.10.sup.6 c/mL in 15 mL and expanded to approximately
4.times.10.sup.7 c/mL over eight days. The outer chamber was filled
with media supplemented with up to 10% BCS (bovine calf serum). On
day six to eight, the inner chamber culture was harvested, washed
with 15 mL SF media and re-innoculated with hybridoma cells.
Bioreactor supernatant and wash were combined and clarified by
centrifugation. The resulting supernatant was filtered through a
0.22 .mu.M filter membrane. For antibody purification, supematants
were diluted 1:1 in high salt binding buffer (1M Glycine/2M NaCl,
pH 9.0), and mAbs were purified using Protein G HiTrap 5 mL column
(GE healthcare). After washing with PBS, bound antibodies were
eluted using 0.1 M Glycine pH=2.7, followed by pH neutralization
using 3 M Tris. Finally, the buffer was exchanged for PBS using
PD-10 gel-filtration columns (GE healthcare), and antibodies were
concentrated using Ultra-15 centrifugal concentrators (Amicon) and
quantified using spectrophotometry.
Commercial Antibodies
[0195] The following commercial antibodies were used in various
studies described herein: Anti-PD-1 antibody clone J116 (#14-9989)
was purchased from eBioscience. Anti-CTLA-4 clone 14D3 (mAb
16-1529) was purchased from eBioscience. Anti-PD-1 clone 192106
(mAb1086) was purchased from R&D systems (#mAb1086). Isotype
control antibody mIgG1, kappa, clone MOPC21 was purchased from
Sigma (#M9269). Isotype controls mIgG1 kappa (mAb 16-4714) and
IgG2a kappa (mAb 16-4724) were purchased from eBioscience.
Binding Analysis
[0196] Protein-based and cell-based ELISA (`CELISA`) experiments
were used to determine apparent binding affinities (reported as
EC50 values). In some cases, the binding of the anti-PD-1
antibodies was compared to that of commercial anti-PD-1 antibodies
J116 (eBiosciences) and Mab1086 (R&D systems).
[0197] A protein ELISA was used for determination of the relative
binding of antibodies to human PD-1/Fc. hPD-1/Fc (R & D
Systems) was immobilized onto Maxisorp 96-well plates (Nunc) by
incubation for 4 h at room temperature (or overnight at 4.degree.
C.). Nonspecific binding sites were blocked by incubation with 3%
BSA in PBST for one hour at room temperature. After coating, the
plates were washed three times with PBST. Dilutions of anti-PD-1
antibodies were prepared in binding buffer (PBS containing 0.1%
Tween 20 and 0.3% BSA) and incubated with the immobilized fusion
protein for one hour at 25.degree. C. After binding, the plates
were washed three times with PBST, incubated for one hour at
25.degree. C. with peroxidase-labeled goat anti-mouse IgG (Southern
Biotech) diluted 1/4,000 in binding buffer, washed again, and
developed using TMB. ELISA results are shown in FIG. 2. The
concentration of half-maximal binding is reported as a measure of
relative binding affinity (Table II).
[0198] Binding to CHO-hPD-1 cells was also assessed by CELISA. For
CELISA, CHO-hPD-1 cells were cultured to 80 to 100 percent
confluency in 50 .mu.L culture medium (DMEM/HAM'S F12, 10% FBS).
Next, 50 .mu.L media containing various concentrations of purified
mAb were added for one hour at 37.degree. C. After three washes
with PBS-Tween, 100 .mu.L goat-anti-mouse-HRP (Southern Biotech cat
#1030-05) (diluted 1:1000 in culture medium) was added for one hour
at 37.degree. C. After three additional washes with PBS-Tween,
immobilized immunoglobulins were visualized with colorimetric
peroxidase substrate TMB (BD Biosciences). Absorbance increase due
to peroxidase activity (450 nm) was measured in a microtiter plate
reader. FIG. 2 shows the dose-response relation between
concentration and binding for antibodies hPD-1.08A and hPD-1.09A.
The results of the protein and cell binding studies are summarized
in Table II.
Kinetic Analysis by Bio-Light Interferometry (ForteBio)
[0199] To further characterize the binding characteristics of the
antibodies, each was profiled using bio-light interferometry on the
Octet system (ForteBio, Menlo Park, Calif.) to elucidate binding
kinetics and calculate equilibrium binding constants. This assay
was performed by coupling PD-1-Fc fusion protein (R&D Systems)
to amine-reactive biosensors (Fortebio) using standard amine
chemistry. Anti-PD-1 mAb binding to and dissociation from the
biosensors was then observed at various antibody concentrations.
Specifically, amine-reactive biosensors were pre-wet by immersing
them in wells containing 0.1M MES pH=5.5 for 5 minutes. The
biosensors were then activated using a 0.1M NHS/0.4M EDC mixture
for 5 minutes. PD-1/Fc fusion protein (R & D systems) was
coupled by immersing the biosensors in a solution of 12 ug/mL
PD-1/Fc in 0.1M MES for 7.5 minutes. The biosensor surface was
quenched using a solution of 1M ethanolamine for 5 minutes.
Biosensors were equilibrated in PBS for 5 minutes. Association of
anti-PD-1 mAbs was observed by placing the biosensors in wells
containing various antibody concentrations (10-80 nM purified
antibody >99% by SDS-PAGE in PBS) and monitoring interferometry
for 30 minutes. Dissociation was measured after transfer of the
biosensors into PBS and monitoring of the interferometry signal for
60 minutes. The observed on and off rates (k.sub.obs and k.sub.d)
were fit using a 1:1 binding global fit model comprising all
concentrations tested, and the equilibrium binding constant K.sub.D
was calculated. Results from the kinetic studies are presented in
Table II, and FIG. 6 below.
TABLE-US-00003 TABLE II Biochemical characterization summary of
murine anti-PD-1 mAbs. Binding Analysis Ligand Blockade Kinetic
Analysis ELISA CELISA FACS FMAT Fortebio Octet EC50 (pM) EC50 (pM)
IC50 (pM) IC50 (pM) k.sub.assoc k.sub.dissoc K.sub.D mAb hPD-1/Fc
hPD-1/CHO PD-L1 PD-L1 PD-L2 1/s 1/Ms M 05A 338 15 1.62E+05 1.11E-04
6.90E-10 06B 135 160 8.32E+04 9.74E-05 1.17E-09 08A 76 79 0.9 0.73
2.1 1.25E+06 3.03E-05 2.41E-11 09A 123 113 0.8 0.90 1.7 1.64E+06
3.60E-05 2.20E-11 13A 485 64 1.46E+05 4.16E-04 2.85E-09 J116 410
349 106 >100 44 8.24E+04 1.50E-04 1.82E-09 mAb1086 59 >10000
>10000 >10000 >10000 2.45E+05 1.68E-04 6.86E-10
[0200] Two of the monoclonal antibodies, hPD-1.08A and hPD-1.09A,
bound considerably more tightly than any other mAb tested using
this assay, with K.sub.D determined to be 24 and 22 .mu.M for
hPD-1.08A and hPD-1.09A, respectively. Compared to the other
anti-PD-1 antibodies tested, the increased affinity is due to a
slower off-rate and a significantly faster on-rate measured for
hPD-1.08A and hPD-1.09A.
Ligand Blockade
[0201] Blockade of ligand binding studied using flow cytometry. CHO
cells expressing human PD-1 were dissociated from adherent culture
flasks and mixed with varying concentrations of anti-PD-1 antibody
and a constant concentration (600 ng/mL) of unlabeled hPD-L1/Fc or
recombinant human PD-L2/Fc fusion protein (both from R&D
Systems) in a 96-well plate. The mixture was equilibrated for 30
minutes on ice, washed three times with FACS buffer (PBS containing
1% BCS and 0.1% sodium azide), and incubated with FITC labeled goat
anti-human Fc for a further 15 minutes on ice. The cells were
washed again with FACS buffer and analyzed by flow cytometry. Data
were analyzed with Prism (GraphPad Software, San Diego, Calif.)
using non-linear regression, and IC50 values were calculated.
[0202] Calculated IC.sub.50 data are summarized in Table II.
Antibodies 05A, 06B and 13A were determined to demonstrate a
K.sub.D between 600 .mu.M and 3 nM for the binding of hPD-1.
Despite the tight binding, these antibodies each demonstrated
IC.sub.50>10 nM for the blockade of hPD-L1 binding to hPD-1. The
commercially available anti-PD-1 antibody J116 (eBiosciences)
weakly competed with PD-L1 for binding, having a calculated IC50
outside the range of this experiment (>100, nM). Control mouse
IgG1 does not compete with PD-L1 for PD-1 binding. In contrast, the
high affinity antibodies hPD-1.08A and hPD-1.09A inhibited PD-L1
binding with IC.sub.50 values below 1 nM, whereas PD-L2 binding was
blocked with IC.sub.50 values around 1-2 nM (Table II). PD-L2 was
reported earlier to bind to PD-1 with a two- to six-fold higher
affinity than does PD-L1 (Youngnak P. et al., 2003, Biochem.
Biophys. Res. Commun. 307, 672-677).
[0203] Ligand blockade was confirmed using a homogeneous
competition assay and detection using fluorometric microvolume
assay technology (FMAT). Briefly, CHO.hPD-1 were dissociated from
adherent culture flasks, mixed with varying concentrations of
anti-PD-1 antibody and a constant concentration (600 ng/mL) of
hPD-L1/Fc or hPD-L2/Fc fusion protein (both from R&D Systems),
labeled with a fluorescent dye (AlexaFluor 647, Invitrogen) in a
96-well plate. The mixture was equilibrated for 90 minutes at
37.degree. C. and read using an AB8200 Cellular Detection Analyzer
(Applied Biosystems, Foster City, Calif.). Data was analyzed with
Prism (GraphPad Software, San Diego, Calif.) using non-linear
regression, and IC50 values were calculated. FIG. 3 shows results
of a dose-response experiment indicating that the magnitude of
ligand blockade is determined by antibody concentration. Binding of
both hPD-L1/Fc and hPD-L2/Fc to CHO-hPD-1 cells can be completely
inhibited by hPD-1.08A, hPD-1.09A and (to a lesser extent) by J116
in a dose-dependent fashion. Calculated IC.sub.50 data are
summarized in Table II. Confirming the results obtained using flow
cytometry, the high affinity antibodies hPD-1.08A and hPD-1.09A
inhibited PD-L1 binding with IC.sub.50 values below 1 nM.
Species Cross-Reactivity
[0204] To assess the species cross-reactivity of the antibodies,
the mouse and cynomolgus macaque PD-1 receptors were cloned by PCR
and stably transfected CHO-K1 cells were generated. The antibodies
were tested for binding to the cynomolgus receptor using a CELISA.
Commercial antibody J116, hPD-1.08A and hPD-1.09A were found to
bind with equal affinity to human and cynomolgus PD-1 and block
binding of hPD-L1/Fc and hPD-L2/Fc to cynomolgus PD-1 with similar
efficacy as compared to human PD-1. This is not surprising because
the amino acid sequence of the extracellular portion of cynomolgus
PD-1 was found to be 97% identical to that of human PD-1. In
addition to PD-1 from cynomolgus macaques, hPD-1.08A and hPD-1.09A
also functionally blocked PD-1 from rhesus macaques in SEB
stimulated blood cell cultures described in Example 3. None of the
antibodies tested bound mouse PD-1 with detectable affinity in any
of the assays used.
[0205] In summary, five anti-PD-1 monoclonal antibodies were
purified and characterized, which were isolated based on their
ability to modulate Jurkat function. These antibodies bound tightly
to PD-1 (with dissociation constants in the 20 .mu.M to 3 nM range)
and were capable of blocking the interaction with both PD-L1 and
PD-L2 with varying IC50 values. Four of these anti-hPD-1 mAbs were
considerably better than the best available commercial anti-PD-1
mAbs. Each of the antibodies, when added in solution acted as
receptor antagonists, ultimately enhancing T cell responses (see
Example 3).
Example 3: Functional Profiling of Anti-PD-1 Antibodies
[0206] Human T Cell Response to SEB is Enhanced by hPD-1.08A and
hPD-1.09A
[0207] Anti-PD-1 antibodies were tested for their capacity to
enhance T cell activity in vitro using blood cells from healthy
volunteers. One assay used to characterize the functional
consequence of blocking human PD-1 receptor utilized Staphylococcus
enterotoxin B (SEB) to engage and activate all T cells expressing
the V.beta.3 and V.beta.8 T cell receptor chain. Healthy human
donor blood was obtained and diluted 110 into culture medium.
Diluted whole blood was plated (150 .mu.l per well) in 96-well
round-bottom plates and pre-incubated for 30-60 min with mAb and
varying concentrations. SEB was then added at various
concentrations ranging from 10 ng/mL to 10 .mu.g/mL. Supernatants
were collected after 2 to 4 days of culture and the amount of IL-2
produced was quantified using ELISA (described in Example 1) or
using standard multiplex technology (Luminex platform--Biosource
cytokine detection kits). Titration of SEB from 100 ng/mL up to 10
.mu.g/mL significantly stimulated IL-2 production by whole-blood
cells. Usually, depending on the donor, 100 to 1000 .mu.g/mL IL-2
was detectable by ELISA 2-4 days after stimulation with 1 .mu.g/mL
of SEB. Addition of hPD-1.08A and hPD-1.09A enhanced IL-2
production over control mouse IgG1, on average 2 to 4 fold at the
highest antibody concentration tested (25 .mu.g/mL). The
stimulation index was averaged for experiments performed with a set
of independent healthy volunteers (FIG. 4). These experiments
demonstrated that both hPD-1.08A and hPD-1.09A enhanced IL-2
production upon SEB stimulation of diluted whole-blood cells. Both
PD-1 and PD-L1 (but not PD-L2) expression levels were upregulated
(quantified by flow cytometry) over time after SEB stimulation of
whole blood cells. Anti-PD-L1 monoclonal antibody (clone MIH5,
Ebiosciences #16-5982) and anti-CTLA-4 (clone 14D3, eBiosciences
#16-1529) also induced an increase in IL-2 production under similar
conditions, a finding that further validated the use of the SEB
stimulation assay to quantify T cell activity after manipulation of
costimulatory pathways (FIG. 4). The enhanced IL-2 production by
anti-PD-1 antibodies was found to be dose-dependent. In addition to
IL-2, by Luminex technology levels of TNF.alpha., IL-17, IL-7, IL-6
and IFN.gamma. were also found to be significantly modulated by
hPD-1.08A and hPD-1.09A. The results of these experiments indicate
that hPD-1.08A and hPD-1.09 can be used to stimulate human T cell
responses.
[0208] Anti-PD-1 antibody, hPD-1.09A, was further tested for its
capacity to enhance T cell activity in vitro using blood cells
derived from cancer patients. Blood from patients with advanced
melanoma (1 patient) or prostate cancer (3 patients) was tested
following the above protocol. Results of the cytokine quantitation
are presented in Table III as fold increase of cytokine produced
when cells are stimulated in the presence of 25 ug/mL hPD-1.09A
compared to SEB stimulation in the absence of antibody. In summary,
hPD-1.09A was found to increase the SEB induced IL-2 production 2
to 3.5 fold for each of the 4 patients. Similarly production of
TNF.alpha., IL-17 and IFN.gamma. was enhanced, and production of
IL-5 and IL-13 was decreased. These experiments indicate that
hPD-1.09A has the ability to stimulate T cell responses in cancer
patients. Further, these experiments suggest a preference towards
Th1 responses.
TABLE-US-00004 TABLE III SEB-stimulated cytokine production in the
presence of hPD-1.09A cancer Fold change in cytokine level patient
type IL-2 TNF.alpha. IFN.gamma. IL-5 IL-6 IL-13 IL-17 A prostate
3.4 2.0 1.9 0.7 2.1 0.8 1.8 B prostate 2.1 1.5 1.2 0.4 2.2 0.6 2.6
C prostate 2.0 2.4 2 0.9 2.4 1.1 2.4 D melanoma 2.0 1.9 1.5 0.4 1.9
0.5 2.0
Human Recall T Cell Response to TT Challenge is Enhanced by
hPD-1.08A and hPD-1.09A
[0209] Another assay used to profile the functional effect of
anti-human PD-1 antibodies blocking receptor interaction with its
natural ligands used the tetanus toxoid (TT) antigen to stimulate
pre-existing memory T cells in healthy donor blood. To this end,
freshly prepared PBMC (2.times.10.sup.5 cells) were plated in 96
well round-bottom plates in complete RPMI 1640 medium (containing
5% heat inactivated human serum), pre-incubated with test
antibodies at varying concentration and stimulated with TT (Astarte
Biologics) at a concentration of 100 ng/mL. The cells were
incubated for 3-7 days at 37.degree. C., 5% CO.sub.2 after which
supernatants were harvested. Cytokine concentrations were
determined by ELISA (IL-2 and IFN-.gamma. ELISA detection antibody
pair sets from eBioscience) and multiplex analysis (Luminex
platform--Biosource cytokine detection kits). Blockade of PD-1
enhanced proliferation and significantly enhanced cytokine
production (FIG. 5) including IFN.gamma. and IL-2 compared to
antigen alone. Luminex analysis revealed that production of the
cytokines GM-CSF, RANTES, and IL-6 are increased upon PD-1
blockage.
Staining of Human PD-1 on Formalin-Fixed Paraffin-Embedded Human
Cells
[0210] Since SEB-stimulated blood cells demonstrated enhanced
expression of PD-1 by flow cytometry, these cells were used to
determine if hPD-1.09A could detect PD-1 in formalin-fixed paraffin
embedded tissue for histological use. Human donor peripheral blood
mononuclear cells were stimulated with 0.1 .mu.g/mL SEB for 3 days,
after which the non-adherent cells (mainly lymphocytes) were
collected, washed twice with PBS and centrifuged (1100 rpm for 5
min.). The cells were fixed for 10 min in 4% formaldehyde, the
cell-pellet was embedded in agarose, dehydrated in ethanol
(subsequently 70%, 80%, 96% and 100%) and xylene, and thereafter
embedded in paraffin. Sections (4 .mu.m) were mounted onto glass
slides and hydrated (xylene, ethanol 100%, 96%, 80%, 70%, PBS
buffer), after which antigen retrieval in heated citrate buffer was
performed using standard methodology. Peroxidase activity was
blocked using 100% methanol including 0.3% H.sub.2O.sub.2 and
slides were rinsed in water and PBS, Tween 0.1%. Sections were
incubated with hPD-1.09A for 1.5 hours at room temperature, rinsed
with PBS-Tween, followed by standard detection methods. Slides were
counterstained with hematoxylin for 30 seconds at room temperature,
dehydrated with xylene, and mounted for microscopical examination.
These experiments showed that lymphocytes derived from SEB
stimulated PBMC cultures stained strongly (when compared to the
isotype control) with hPD-1.09A, as opposed to unstimulated PBMC
cultures, indicating that hPD-1.09A is useful as a diagnostic
reagent.
Example 4: Anti-PD-1 Antibodies Sequences and Subsequent
Humanization
[0211] Cloning of Immunoglobulin cDNAs
[0212] Using degenerate primer PCR-based methods, the DNA sequences
encoding the variable regions of the mouse antibodies expressed by
hybridomas hPD-1.08A and hPD-1.09A were determined. Briefly, gene
specific cDNAs for the heavy and light chains were generated using
the iScript Select cDNA synthesis kit (Biorad #1708896) according
to the manufacturer's instructions. PCR primers used were based on
the Ig-primer set (Novagen #69831-3). Degenerate PCR reactions were
carried out using Taq polymerase according to the Novagen primer
set protocol. PCR products were analyzed by agarose gel
electrophoresis. The expected amplicon size for both the heavy and
light chain variable region is about 500 base pairs. Two .mu.l of
Taq-amplified PCR product from reactions which yielded an
appropriate band were cloned into the pCR4 TOPO vector (Invitrogen
#K4595-40) and transformed into DH5-alpha E. coli as directed by
the manufacturer.
[0213] Clones were screened by colony PCR using universal M13
forward and reverse primers and two to three clones from each
reaction were chosen for DNA sequencing analysis. Clones were
sequenced in both directions using universal primers M13 forward,
M13 reverse, T3 and T7. Results of each sequencing reaction for
each clone were analyzed using Segman. Consensus sequences were
searched against databases of germline and rearranged Ig Variable
region sequences using NCBI Ig-Blast
(http://www.ncbi.nlm.nih.gov/projects/igblast/). Blast results for
hPD-1.08A identified a productively (in-frame) rearranged heavy
chain with no stop codons introduced. Light chain clones were
identified which encode two different sequences; one is a
productively (in-frame) rearranged light chain with no stop codons
introduced, the other is a non-productively rearranged sequence
containing a frame-shift leading to a stop codon in the FR4 region.
The non-productive sterile transcript observed likely originates
from the myeloma fusion partner (Carroll W. L. et al., Mol.
Immunol. 25:991-995 (1988) and was ruled out.
[0214] Blast results for hPD-1.09A identified productively
(in-frame) rearranged heavy and light chains with no stop codons
introduced. The amino acid sequences of the expressed proteins were
been confirmed by mass spectrometry. The sequences are disclosed in
the attached Sequence Listing and listed in table IV.
TABLE-US-00005 TABLE IV Sequence ID numbers for murine anti-human
PD-1 antibodies of this invention SEQ ID NO: Description 1
hPD-1.08A heavy chain variable region (DNA) 2 hPD-1.08A light chain
variable region (DNA) 3 hPD-1.09A heavy chain variable region (DNA)
4 hPD-1.09A light chain variable region (DNA) 5 hPD-1.08A heavy
chain variable region (AA) 6 hPD-1.08A light chain variable region
(AA) 7 hPD-1.09A heavy chain variable region (AA) 8 hPD-1.09A light
chain variable region (AA) 9 hPD-1.08A light chain CDR1 (AA) 10
hPD-1.08A light chain CDR2 (AA) 11 hPD-1.08A light chain CDR3 (AA)
12 hPD-1.08A heavy chain CDR1 (AA) 13 hPD-1.08A heavy chain CDR2
(AA) 14 hPD-1.08A heavy chain CDR3 (AA) 15 hPD-1.09A light chain
CDR1 (AA) 16 hPD-1.09A light chain CDR2 (AA) 17 hPD-1.09A light
chain CDR3 (AA) 18 hPD-1.09A heavy chain CDR1 (AA) 19 hPD-1.09A
heavy chain CDR2 (AA) 20 hPD-1.09A heavy chain CDR3 (AA) 21 109A-H
heavy chain variable region (DNA) 22 Codon optimized 109A-H heavy
chain variable region (DNA) 23 Codon optimized 409A-H heavy chain
full length (DNA) 24 K09A-L-11 light chain variable region (DNA) 25
K09A-L-16 light chain variable region (DNA) 26 K09A-L-17 light
chain variable region (DNA) 27 Codon optimized K09A-L-11 light
chain variable region (DNA) 28 Codon optimized K09A-L-16 light
chain variable region (DNA) 29 Codon optimized K09A-L-17 light
chain variable region (DNA) 30 109A-H heavy chain variable region
(AA) 31 409A-H heavy chain full length (AA) 32 K09A-L-11 light
chain variable region (AA) 33 K09A-L-16 light chain variable region
(AA) 34 K09A-L-17 light chain variable region (AA) 35 109A-H heavy
chain full length (AA) 36 K09A-L-11 light chain full length (AA) 37
K09A-L-16 light chain full length (AA) 38 K09A-L-17 light chain
full length (AA)
[0215] CDR and framework regions are annotated according to Kabat
E. A., et al., 1991, Sequences of proteins of Immunological
interest, In: NIH Publication No. 91-3242, US Department of Health
and Human Services, Bethesda, Md.
Construction and Expression of Chimeric c109A Antibody
[0216] Chimeric light and heavy chains were constructed by linking
the PCR-cloned cDNAs of mouse hPD-1.09A V.sub.L and V.sub.H regions
to human kappa and IgG1 constant regions, respectively. The 5' and
3' ends of the mouse cDNA sequences were modified using PCR primers
designed to add a suitable leader sequence to each chain, and
restriction sites to enable cloning into existing recombinant
antibody expression vectors.
[0217] COS-7 cells (0.7 mL at 10.sup.7/mL) were electroporated with
10 .mu.g of each of the chimeric heavy and light chain expression
plasmids. These cells were then cultured in 8 mL growth medium for
three days. A sandwich ELISA was used to measure the antibody
concentrations in the supernatants from the COS-7 transfections.
This showed that the transfected COS-7 cells secreted about 295
ng/mL of the chimeric IgG.sub.1-kappa antibody in three separate
transfections.
[0218] Binding of the chimeric antibody produced by the transfected
COS-7 cells was measured using PD-1 binding ELISA and CELISA (see
Example 2) and was shown to bind to PD-1 with comparable affinity
to that of the murine antibody.
Humanized Antibody Design
[0219] The hPD-1.09A antibody was humanized by MRCT (Cambridge UK)
using CDR grafting technology (see, e.g., U.S. Pat. No. 5,225,539).
Briefly, the variable chain sequences of the murine antibody
hPD-1.09A were compared to those available in the Research
Collaboratory for Structural Bioinformatics (RCSB) protein
databank. A homology model of hPD-1.09A was generated based on the
nearest V.sub.H and VK structures. Human sequences with highest
identity to hPD-1.09A were identified and analyzed. (Foote and
Winter, J. Mol. Biol. 224:487-499 (1992); Morea V. et al., Methods
20:267-279 (2000); Chothia C. et al., J. Mol. Biol. 186:651-663
(1985).) The most appropriate human frameworks on which to build
the CDR grafted heavy and light chains were identified.
[0220] For the heavy chain, the framework encoded by genbank
accession #AB063829 was determined to be the most appropriate.
Analysis of the hPD-1.09A VK sequence shows that its CDR1 length
(15 residues) is not found in any human VK. For this reason,
frameworks of three different CDR1 lengths (11, 16 and 17 residues)
were analyzed in order to test which CDR1 length would reproduce
the behavior of hPD-1.09A VK. The human VK sequences with highest
identity to hPD-1.09A VK at selected residues important in the
structure and with CDR1 lengths 11, 16 and 17 were identified. The
framework of genbank accession #M29469 was selected on which to
base K109A-L-11. The framework from genbank accession #AB064135 was
selected on which to base K09A-L-16 and the framework from genbank
accession #X72431 was chosen on which to base K09A-L-17.
[0221] Straight grafts were performed to generate expression
constructs for each chain. The DNA and protein sequences of 109A-H,
K09A-L-11, K09A-L-16 and K09A-L-17 are disclosed in the attached
Sequence Listing (Table IV).
[0222] An IgG4 version of the humanized h109A antibody was
produced, with the stabilizing Adair mutation (Angal S. et al.,
Mol. Immuol. 30:105-108 (1993)), where serine 241 (Kabat numbering)
is converted to proline. This sequence is disclosed in SEQ ID NOS:
23 and 31.
Example 5: Binding Characteristics and Functional Properties of
Humanized Anti-PD-1 Antibodies
Production and Purification
[0223] Humanized antibodies h409A11, h409A16 and h409A17 were
produced by transient transfection of CHO-S cells. Cells were grown
in CD-CHO (Gibco) and C5467 media (Sigma) for 8 days in shaker
flasks. Antibodies were purified from cell supernatants by Protein
A chromatography, washed, eluted using 1 M acetic acid and
neutralized using 3 M Tris. Finally, the buffer was exchanged for
100 mM acetic acid which had been adjusted to pH 5.5 with 1 M Tris
base.
Binding and Kinetic Analysis
[0224] Protein-based and cell-based ELISAs to determine apparent
binding affinities (reported as 20 EC50 values) were performed as
described in Example 2. The humanized anti-PD-1 antibodies each
bound to PD-1/Fc and cellularly expressed PD-1 with comparable EC50
values to the murine parent antibody (Table V).
[0225] Kinetic binding characteristics of the antibodies were also
performed using bio-light interferometry as described in Example 2
(FIG. 6). Two of the humanized antibodies, h409A11 and h409A16,
bound considerably more tightly than any other mAb tested using
this assay, with K.sub.D determined to be 29 and 27 .mu.M for
h409A11 and h409A16, respectively (Table V). Compared to the other
anti-PD-1 antibodies tested, the increased affinity is mainly due
to a slower off-rate. Similar to the murine parental antibodies,
the humanized anti-PD-1 antibodies h409A11, h409A16 demonstrated
binding to cynomolgous PD-1 with K.sub.D determined to be below 120
.mu.M.
Ligand Blockade
[0226] The ability of the humanized antibodies to block the binding
of PD-L1 and PD-L2 to PD-1 was measured using a homogeneous
competition assay and detection using an FMAT competition assay as
described in Example 2.
[0227] Binding of both hPD-L1/Fc and hPD-L2/Fc to CHO-hPD-1 cells
can be completely inhibited in a dose-dependent fashion by any of
the humanized antibodies tested. Calculated IC.sub.50 data are
summarized in Table V. Similarly to the parent murine antibody
hPD-1.09A, each of the humanized mAbs, h409A11, h409A16 and h409A17
inhibited PD-L1 and PD-L2 binding with IC.sub.50 values below 1 nM.
Similar to the murine parental antibodies, the humanized anti-PD-1
antibodies h409A11, h409A16 and h409A17 demonstrated inhibition of
ligand binding to cynomolgous PD-1 with calculated IC.sub.50 values
under about 1 nM.
TABLE-US-00006 TABLE V Binding characteristics of humanized
anti-hPD-1 antibodies of the invention Binding Analysis Ligand
Blockade Kinetic Analysis ELISA CELISA FMAT Fortebio Octet EC50
(pM) EC50 (pM) IC50 (pM) k.sub.assoc k.sub.dissoc K.sub.D mAb
hPD-1/Fc hPD-1/CHO PD-L1 PD-L2 1/s 1/Ms M h409A11 76 62 625 695
1.04E+06 3.05E-05 2.93E-11 h409A16 90 63 696 810 9.97E+05 2.72E-05
2.73E-11 h409A17 88 83 818 463 1.00E+06 1.91E-04 1.91E-10
Human T Cell Response to SEB is Enhanced by Humanized mAbs
[0228] Humanized anti-PD-1 antibodies were tested for their
capacity to enhance T cell activity in vitro using blood cells from
healthy volunteers as described in Example 3. Supernatants were
collected after 4 days of culture and the amount of IL-2 produced
was quantified using ELISA The humanized PD-1 antibodies
demonstrated the capacity to increase IL-2 production stimulated by
SEB (FIG. 7). Additionally, the humanized PD-1 antibodies increased
SEB induced IL-2 production in cancer patient blood, similar to
what is described in Example 3.
[0229] In summary, the humanized mAbs h409A11, h409A16, and h409A17
retained all functional activity during the humanization process.
The h409A11 and h409A16 mAbs fully retained the affinity of the
mouse parental antibody hPD109A upon humanization.
Sequence CWU 1
1
381435DNAArtificial SequencehPD-1.08A heavy chain variable region
1atgrgatgga gctgtatcat kctctttttg gtagcaacag ctacaggtgt ccactcccag
60gtccaactgc agcagcctgg ggctgaactg gtgaagcctg gggcttcagt gaagttgtcc
120tgcaaggcct ctggctacac cttcaccagt tattatctgt actggatgaa
acagaggcct 180ggacaaggcc ttgagtggat tgggggggtt aatcctagta
atggtggtac taacttcagt 240gagaagttca agagcaaggc cacactgact
gtagacaaat cctccagcac agcctacatg 300caactcagca gcctgacatc
tgaggactct gcggtctatt actgtacaag aagggattct 360aactacgacg
ggggctttga ctactggggc caaggcacta ctctcacagt ctcctcagcc
420aaaacgacac cccca 4352453DNAArtificial SequencehPD-1.08A light
chain variable region 2atggagacag acacactcct gctatgggta ctgctgctct
gggttccagg ttccactggt 60gacattgtgc tgacacagtc tcctacttcc ttagctgtat
ctctggggca gagggccacc 120atctcatgca gggccagcaa aagtgtcagt
acatctggct ttagttattt gcactggtac 180caacagaaac caggacagcc
acccaaactc ctcatctttc ttgcatccaa cctagagtct 240ggggtccctg
ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat
300cctgtggagg aggaggacgc tgcaacctat tattgtcagc acagttggga
gcttccgctc 360acgttcggtg ctgggaccaa gctggagctg aaacgggctg
atgctgcacc aactgtatcc 420atcttcccac catccagtaa gcttgggaag ggc
4533464DNAArtificial SequencehPD-1.09A heavy chain variable region
3atgraatgca gctgggttat yctctttttg gtagcaacag ctacaggtgt ccactcccag
60gtccaactgc agcagcctgg ggctgaactg gtgaagcctg ggacttcagt gaagttgtcc
120tgcaaggctt ctggctacac cttcaccaac tactatatgt actgggtgaa
gcagaggcct 180ggacaaggcc ttgagtggat tggggggatt aatcctagca
atggtggtac taacttcaat 240gagaagttca agaacaaggc cacactgact
gtagacagtt cctccagcac aacctacatg 300caactcagca gcctgacatc
tgaggactct gcggtctatt actgtacaag aagggattat 360aggttcgaca
tgggctttga ctactggggc caaggcacca ctctcacagt ctcctcagcc
420aaaacgacac ccccatccgt ytatcccbtg gcccctggaa gctt
4644438DNAArtificial SequencehPD-1.09A light chain variable region
4atggagwcag acacactsct gytatgggta ctgctgctct gggttccagg ttccactggc
60gacattgtgc tgacacagtc tcctgcttcc ttagctgtat ctctgggaca gagggccgcc
120atctcatgca gggccagcaa aggtgtcagt acatctggct atagttattt
gcactggtac 180caacagaaac caggacagtc acccaaactc ctcatctatc
ttgcatccta cctagaatct 240ggggtccctg ccaggttcag tggcagtggg
tctgggacag acttcaccct caacatccat 300cctgtggagg aggaggatgc
tgcaacctat tactgtcagc acagtaggga ccttccgctc 360acgttcggta
ctgggaccaa gctggagctg aaacgggctg atgctgcacc aactgtatcc
420atcttcccac catccagt 4385122PRTArtificial SequencehPD-1.08A heavy
chain variable region 5Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu
Val Lys Pro Gly Ala1 5 10 15Ser Val Lys Leu Ser Cys Lys Ala Ser Gly
Tyr Thr Phe Thr Ser Tyr 20 25 30Tyr Leu Tyr Trp Met Lys Gln Arg Pro
Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Gly Val Asn Pro Ser Asn Gly
Gly Thr Asn Phe Ser Glu Lys Phe 50 55 60Lys Ser Lys Ala Thr Leu Thr
Val Asp Lys Ser Ser Ser Thr Ala Tyr65 70 75 80Met Gln Leu Ser Ser
Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95Thr Arg Arg Asp
Ser Asn Tyr Asp Gly Gly Phe Asp Tyr Trp Gly Gln 100 105 110Gly Thr
Thr Leu Thr Val Ser Ser Ala Lys 115 1206111PRTArtificial
SequencehPD-1.08A light chain variable region 6Asp Ile Val Leu Thr
Gln Ser Pro Thr Ser Leu Ala Val Ser Leu Gly1 5 10 15Gln Arg Ala Thr
Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 20 25 30Gly Phe Ser
Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45Lys Leu
Leu Ile Phe Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His65 70 75
80Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Trp
85 90 95Glu Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 1107122PRTArtificial SequencehPD-1.09A heavy chain variable
region 7Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly
Thr1 5 10 15Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
Asn Tyr 20 25 30Tyr Met Tyr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe
Asn Glu Lys Phe 50 55 60Lys Asn Lys Ala Thr Leu Thr Val Asp Ser Ser
Ser Ser Thr Thr Tyr65 70 75 80Met Gln Leu Ser Ser Leu Thr Ser Glu
Asp Ser Ala Val Tyr Tyr Cys 85 90 95Thr Arg Arg Asp Tyr Arg Phe Asp
Met Gly Phe Asp Tyr Trp Gly Gln 100 105 110Gly Thr Thr Leu Thr Val
Ser Ser Ala Lys 115 1208111PRTArtificial SequencehPD-1.09A light
chain variable region 8Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu
Ala Val Ser Leu Gly1 5 10 15Gln Arg Ala Ala Ile Ser Cys Arg Ala Ser
Lys Gly Val Ser Thr Ser 20 25 30Gly Tyr Ser Tyr Leu His Trp Tyr Gln
Gln Lys Pro Gly Gln Ser Pro 35 40 45Lys Leu Leu Ile Tyr Leu Ala Ser
Tyr Leu Glu Ser Gly Val Pro Ala 50 55 60Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Asn Ile His65 70 75 80Pro Val Glu Glu Glu
Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg 85 90 95Asp Leu Pro Leu
Thr Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys 100 105
110915PRTArtificial SequencehPD-1.08A light chain CDR1 9Arg Ala Ser
Lys Ser Val Ser Thr Ser Gly Phe Ser Tyr Leu His1 5 10
15107PRTArtificial SequencehPD-1.08A light chain CDR2 10Leu Ala Ser
Asn Leu Glu Ser1 5119PRTArtificial SequencehPD-1-08A light chain
CDR3 11Gln His Ser Trp Glu Leu Pro Leu Thr1 5125PRTArtificial
SequencehPD-1.08A heavy chain CDR1 12Ser Tyr Tyr Leu Tyr1
51317PRTArtificial SequencehPD-1.08A heavy chain CDR2 13Gly Val Asn
Pro Ser Asn Gly Gly Thr Asn Phe Ser Glu Lys Phe Lys1 5 10
15Ser1411PRTArtificial SequencehPD-1.08A heavy chain CDR3 14Arg Asp
Ser Asn Tyr Asp Gly Gly Phe Asp Tyr1 5 101515PRTArtificial
SequencehPD-1.09A light chain CDR1 15Arg Ala Ser Lys Gly Val Ser
Thr Ser Gly Tyr Ser Tyr Leu His1 5 10 15167PRTArtificial
SequencehPD-1.09A light chain CDR2 16Leu Ala Ser Tyr Leu Glu Ser1
5179PRTArtificial SequencehPD-1.09A light chain CDR3 17Gln His Ser
Arg Asp Leu Pro Leu Thr1 5185PRTArtificial SequencehPD-1.09A heavy
chain CDR1 18Asn Tyr Tyr Met Tyr1 51917PRTArtificial
SequencehPD-1.09A heavy chain CDR2 19Gly Ile Asn Pro Ser Asn Gly
Gly Thr Asn Phe Asn Glu Lys Phe Lys1 5 10 15Asn2011PRTArtificial
SequencehPD-1.09A heavy chain CDR3 20Arg Asp Tyr Arg Phe Asp Met
Gly Phe Asp Tyr1 5 1021417DNAArtificial Sequence109A-H heavy chain
variable regionsig_peptide(1)..(57) 21atggactgga cctggagcat
ccttttcttg gtggcagcac caacaggagc ccactcccaa 60gtgcagctgg tgcagtctgg
agttgaagtg aagaagcccg gggcctcagt gaaggtctcc 120tgcaaggctt
ctggctacac ctttaccaac tactatatgt actgggtgcg acaggcccct
180ggacaagggc ttgagtggat gggagggatt aatcctagca atggtggtac
taacttcaat 240gagaagttca agaacagagt caccttgacc acagactcat
ccacgaccac agcctacatg 300gaactgaaga gcctgcaatt tgacgacacg
gccgtttatt actgtgcgag aagggattat 360aggttcgaca tgggctttga
ctactggggc caagggacca cggtcaccgt ctcgagc 41722417DNAArtificial
SequenceCodon optimized 109A-H heavy chain variable
regionsig_peptide(1)..(57) 22atggactgga cctggtctat cctgttcctg
gtggccgctc ctaccggcgc tcactcccag 60gtgcagctgg tgcagtccgg cgtggaggtg
aagaagcctg gcgcctccgt caaggtgtcc 120tgcaaggcct ccggctacac
cttcaccaac tactacatgt actgggtgcg gcaggctccc 180ggccagggac
tggagtggat gggcggcatc aacccttcca acggcggcac caacttcaac
240gagaagttca agaaccgggt gaccctgacc accgactcct ccaccaccac
cgcctacatg 300gagctgaagt ccctgcagtt cgacgacacc gccgtgtact
actgcgccag gcgggactac 360cggttcgaca tgggcttcga ctactggggc
cagggcacca ccgtgaccgt gtcctcc 417231398DNAArtificial SequenceCodon
optimized 409A-H heavy chain full lengthsig_peptide(1)..(57)
23atggccgtgc tgggcctgct gttctgcctg gtgaccttcc cttcctgcgt gctgtcccag
60gtgcagctgg tgcagtccgg cgtggaggtg aagaagcctg gcgcctccgt caaggtgtcc
120tgtaaggcct ccggctacac cttcaccaac tactacatgt actgggtgcg
gcaggcccca 180ggccagggac tggagtggat gggcggcatc aacccttcca
acggcggcac caacttcaac 240gagaagttca agaaccgggt gaccctgacc
accgactcct ccaccacaac cgcctacatg 300gaactgaagt ccctgcagtt
cgacgacacc gccgtgtact actgcgccag gcgggactac 360cggttcgaca
tgggcttcga ctactggggc cagggcacca ccgtgaccgt gtcctccgct
420agcaccaagg gcccttccgt gttccctctg gccccttgct cccggtccac
ctccgagtcc 480accgccgctc tgggctgtct ggtgaaggac tacttccctg
agcctgtgac cgtgagctgg 540aactctggcg ccctgacctc cggcgtgcac
accttccctg ccgtgctgca gtcctccggc 600ctgtactccc tgtcctccgt
ggtgaccgtg ccttcctcct ccctgggcac caagacctac 660acctgcaacg
tggaccacaa gccttccaac accaaggtgg acaagcgggt ggagtccaag
720tacggccctc cttgccctcc ctgccctgcc cctgagttcc tgggcggacc
ctccgtgttc 780ctgttccctc ctaagcctaa ggacaccctg atgatctccc
ggacccctga ggtgacctgc 840gtggtggtgg acgtgtccca ggaagatcct
gaggtccagt tcaattggta cgtggatggc 900gtggaggtgc acaacgccaa
gaccaagcct cgggaggaac agttcaactc cacctaccgg 960gtggtgtctg
tgctgaccgt gctgcaccag gactggctga acggcaagga atacaagtgc
1020aaggtcagca acaagggcct gccctcctcc atcgagaaaa ccatctccaa
ggccaagggc 1080cagcctcgcg agcctcaggt gtacaccctg cctcctagcc
aggaagagat gaccaagaat 1140caggtgtccc tgacatgcct ggtgaagggc
ttctaccctt ccgatatcgc cgtggagtgg 1200gagagcaacg gccagccaga
gaacaactac aagaccaccc ctcctgtgct ggactccgac 1260ggctccttct
tcctgtactc caggctgacc gtggacaagt cccggtggca ggaaggcaac
1320gtcttttcct gctccgtgat gcacgaggcc ctgcacaacc actacaccca
gaagtccctg 1380tccctgtctc tgggcaag 139824393DNAArtificial
SequenceK09A-L-11 light chain variable regionsig_peptide(1)..(60)
24atggaagccc cagctcagct tctcttcctc ctgctactct ggctcccaga taccaccgga
60gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc
120ctctcctgca gggccagcaa aggtgtcagt acatctggct atagttattt
gcactggtat 180caacagaaac ctggccaggc tcccaggctc ctcatctatc
ttgcatccta cctagaatct 240ggcgtcccag ccaggttcag tggtagtggg
tctgggacag acttcactct caccatcagc 300agcctagagc ctgaagattt
tgcagtttat tactgtcagc acagcaggga ccttccgctc 360acgttcggcg
gagggaccaa agtggagatc aaa 39325393DNAArtificial SequenceK09A-L-16
light chain variable regionsig_peptide(1)..(60) 25atggaaaccc
cagcgcagct tctcttcctc ctgctactct ggctcccaga taccaccgga 60gaaattgtgc
tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
120atctcctgca gggccagcaa aggtgtcagt acatctggct atagttattt
gcattggtac 180ctccagaagc cagggcagtc tccacagctc ctgatctatc
ttgcatccta cctagaatct 240ggggtccctg acaggttcag tggcagtgga
tcaggcacag attttacact gaaaatcagc 300agagtggagg ctgaggatgt
tggggtttat tactgccagc atagtaggga ccttccgctc 360acgtttggcc
aggggaccaa gctggagatc aaa 39326393DNAArtificial SequenceK09A-L-17
light chain variable regionsig_peptide(1)..(60) 26atgaggctcc
ctgctcagct cctggggctg ctaatgctct gggtctctgg atccagtggg 60gatattgtga
tgacccagac tccactctcc ctgcccgtca cccctggaga gccggcctcc
120atctcctgca gggccagcaa aggtgtcagt acatctggct atagttattt
gcattggtat 180ctgcagaagc cagggcagtc tccacagctc ctgatctatc
ttgcatccta cctagaatct 240ggagtcccag acaggttcag tggcagtggg
tcaggcactg ctttcacact gaaaatcagc 300agggtggagg ctgaggatgt
tggactttat tactgccagc atagtaggga ccttccgctc 360acgtttggcc
aggggaccaa gctggagatc aaa 39327390DNAArtificial SequenceCodon
optimized K09A-L-11 light chain variable regionsig_peptide(1)..(57)
27atggcccctg tgcagctgct gggcctgctg gtgctgttcc tgcctgccat gcggtgcgag
60atcgtgctga cccagtcccc tgccaccctg tccctgagcc ctggcgagcg ggctaccctg
120agctgcagag cctccaaggg cgtgtccacc tccggctact cctacctgca
ctggtatcag 180cagaagccag gccaggcccc tcggctgctg atctacctgg
cctcctacct ggagtccggc 240gtgcctgccc ggttctccgg ctccggaagc
ggcaccgact tcaccctgac catctcctcc 300ctggagcctg aggacttcgc
cgtgtactac tgccagcact cccgggacct gcctctgacc 360tttggcggcg
gaacaaaggt ggagatcaag 39028390DNAArtificial SequenceCodon optimized
K09A-L-16 light chain variable regionsig_peptide(1)..(57)
28atggcccctg tgcagctgct gggcctgctg gtgctgttcc tgcctgccat gcggtgcgag
60atcgtgctga cccagtcccc tctgtccctg cctgtgaccc ctggcgagcc tgcctccatc
120tcctgccggg cctccaaggg cgtgtccacc tccggctact cctacctgca
ctggtatctg 180cagaagcctg gccagtcccc ccagctgctg atctacctgg
cctcctacct ggagtccggc 240gtgcctgacc ggttctccgg ctccggcagc
ggcaccgact tcaccctgaa gatctcccgg 300gtggaggccg aggacgtggg
cgtgtactac tgccagcact cccgggacct gcctctgacc 360ttcggccagg
gcaccaagct ggagatcaag 39029390DNAArtificial SequenceCodon optimized
K09A-L-17 light chain variable regionsig_peptide(1)..(57)
29atggcccctg tgcagctgct gggcctgctg gtgctgttcc tgcctgccat gcggtgcgac
60atcgtgatga cccagacccc tctgtccctg cctgtgaccc ctggcgagcc tgcctccatc
120tcctgccggg cctccaaggg cgtgtccacc tccggctact cctacctgca
ctggtatctg 180cagaagcctg gccagtcccc tcagctgctg atctacctgg
cctcctacct ggagtccggc 240gtgcctgacc ggttctccgg ctccggaagc
ggcaccgctt ttaccctgaa gatctccaga 300gtggaggccg aggacgtggg
cctgtactac tgccagcact cccgggacct gcctctgacc 360ttcggccagg
gcaccaagct ggagatcaag 39030139PRTArtificial Sequence109A-H heavy
chain variable regionsig_peptide(1)..(19) 30Met Asp Trp Thr Trp Ser
Ile Leu Phe Leu Val Ala Ala Pro Thr Gly1 5 10 15Ala His Ser Gln Val
Gln Leu Val Gln Ser Gly Val Glu Val Lys Lys 20 25 30Pro Gly Ala Ser
Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Asn Tyr
Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu 50 55 60Glu Trp
Met Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn65 70 75
80Glu Lys Phe Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr
85 90 95Thr Ala Tyr Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala
Val 100 105 110Tyr Tyr Cys Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly
Phe Asp Tyr 115 120 125Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
130 13531466PRTArtificial Sequence409A-H heavy chain full
lengthsig_peptide(1)..(19) 31Met Ala Val Leu Gly Leu Leu Phe Cys
Leu Val Thr Phe Pro Ser Cys1 5 10 15Val Leu Ser Gln Val Gln Leu Val
Gln Ser Gly Val Glu Val Lys Lys 20 25 30Pro Gly Ala Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Asn Tyr Tyr Met Tyr
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu 50 55 60Glu Trp Met Gly Gly
Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn65 70 75 80Glu Lys Phe
Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr 85 90 95Thr Ala
Tyr Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val 100 105
110Tyr Tyr Cys Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr
115 120 125Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr
Lys Gly 130 135 140Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser
Thr Ser Glu Ser145 150 155 160Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro Val 165 170 175Thr Val Ser Trp Asn Ser Gly
Ala Leu Thr Ser Gly Val His Thr Phe 180 185 190Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 195 200 205Thr Val Pro
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val 210 215 220Asp
His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys225 230
235 240Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly
Gly 245 250 255Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
Leu Met Ile 260 265 270Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
Asp Val Ser Gln Glu 275 280 285Asp Pro Glu Val Gln Phe Asn Trp Tyr
Val Asp Gly Val Glu Val His 290 295 300Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Phe Asn Ser Thr Tyr Arg305 310 315 320Val Val
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 325 330
335Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
340 345 350Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
Val Tyr 355 360 365Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
Gln Val Ser Leu 370 375 380Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
Asp Ile Ala Val Glu Trp385 390 395 400Glu Ser Asn Gly Gln Pro Glu
Asn Asn Tyr Lys Thr Thr Pro Pro Val 405 410 415Leu Asp Ser Asp Gly
Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp 420 425 430Lys Ser Arg
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His 435 440 445Glu
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu 450 455
460Gly Lys46532130PRTArtificial SequenceK09A-L-11 light chain
variable regionsig_peptide(1)..(19) 32Met Ala Pro Val Gln Leu Leu
Gly Leu Leu Val Leu Phe Leu Pro Ala1 5 10 15Met Arg Cys Glu Ile Val
Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu 20 25 30Ser Pro Gly Glu Arg
Ala Thr Leu Ser Cys Arg Ala Ser Lys Gly Val 35 40 45Ser Thr Ser Gly
Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly 50 55 60Gln Ala Pro
Arg Leu Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly65 70 75 80Val
Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 85 90
95Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln
100 105 110His Ser Arg Asp Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys
Val Glu 115 120 125Ile Lys 13033130PRTArtificial SequenceK09A-L-16
light chain variable regionsig_peptide(1)..(19) 33Met Ala Pro Val
Gln Leu Leu Gly Leu Leu Val Leu Phe Leu Pro Ala1 5 10 15Met Arg Cys
Glu Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Pro Val 20 25 30Thr Pro
Gly Glu Pro Ala Ser Ile Ser Cys Arg Ala Ser Lys Gly Val 35 40 45Ser
Thr Ser Gly Tyr Ser Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly 50 55
60Gln Ser Pro Gln Leu Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly65
70 75 80Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
Leu 85 90 95Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
Cys Gln 100 105 110His Ser Arg Asp Leu Pro Leu Thr Phe Gly Gln Gly
Thr Lys Leu Glu 115 120 125Ile Lys 13034130PRTArtificial
SequenceK09A-L-17 light chain variable regionsig_peptide(1)..(19)
34Met Ala Pro Val Gln Leu Leu Gly Leu Leu Val Leu Phe Leu Pro Ala1
5 10 15Met Arg Cys Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro
Val 20 25 30Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ala Ser Lys
Gly Val 35 40 45Ser Thr Ser Gly Tyr Ser Tyr Leu His Trp Tyr Leu Gln
Lys Pro Gly 50 55 60Gln Ser Pro Gln Leu Leu Ile Tyr Leu Ala Ser Tyr
Leu Glu Ser Gly65 70 75 80Val Pro Asp Arg Phe Ser Gly Ser Gly Ser
Gly Thr Ala Phe Thr Leu 85 90 95Lys Ile Ser Arg Val Glu Ala Glu Asp
Val Gly Leu Tyr Tyr Cys Gln 100 105 110His Ser Arg Asp Leu Pro Leu
Thr Phe Gly Gln Gly Thr Lys Leu Glu 115 120 125Ile Lys
13035469PRTArtificial Sequence109A-H heavy chain full
lengthsig_peptide(1)..(19) 35Met Ala Val Leu Gly Leu Leu Phe Cys
Leu Val Thr Phe Pro Ser Cys1 5 10 15Val Leu Ser Gln Val Gln Leu Val
Gln Ser Gly Val Glu Val Lys Lys 20 25 30Pro Gly Ala Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Asn Tyr Tyr Met Tyr
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu 50 55 60Glu Trp Met Gly Gly
Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn65 70 75 80Glu Lys Phe
Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr 85 90 95Thr Ala
Tyr Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val 100 105
110Tyr Tyr Cys Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr
115 120 125Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr
Lys Gly 130 135 140Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
Thr Ser Gly Gly145 150 155 160Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr Phe Pro Glu Pro Val 165 170 175Thr Val Ser Trp Asn Ser Gly
Ala Leu Thr Ser Gly Val His Thr Phe 180 185 190Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 195 200 205Thr Val Pro
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 210 215 220Asn
His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys225 230
235 240Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
Leu 245 250 255Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
Lys Asp Thr 260 265 270Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
Val Val Val Asp Val 275 280 285Ser His Glu Asp Pro Glu Val Lys Phe
Asn Trp Tyr Val Asp Gly Val 290 295 300Glu Val His Asn Ala Lys Thr
Lys Pro Arg Glu Glu Gln Tyr Asn Ser305 310 315 320Thr Tyr Arg Val
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 325 330 335Asn Gly
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 340 345
350Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
355 360 365Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
Asn Gln 370 375 380Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
Ser Asp Ile Ala385 390 395 400Val Glu Trp Glu Ser Asn Gly Gln Pro
Glu Asn Asn Tyr Lys Thr Thr 405 410 415Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe Leu Tyr Ser Lys Leu 420 425 430Thr Val Asp Lys Ser
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 435 440 445Val Met His
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 450 455 460Leu
Ser Pro Gly Lys46536237PRTArtificial SequenceK09A-L-11 light chain
full lengthsig_peptide(1)..(19) 36Met Ala Pro Val Gln Leu Leu Gly
Leu Leu Val Leu Phe Leu Pro Ala1 5 10 15Met Arg Cys Glu Ile Val Leu
Thr Gln Ser Pro Ala Thr Leu Ser Leu 20 25 30Ser Pro Gly Glu Arg Ala
Thr Leu Ser Cys Arg Ala Ser Lys Gly Val 35 40 45Ser Thr Ser Gly Tyr
Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly 50 55 60Gln Ala Pro Arg
Leu Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly65 70 75 80Val Pro
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 85 90 95Thr
Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln 100 105
110His Ser Arg Asp Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu
115 120 125Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro
Pro Ser 130 135 140Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val
Cys Leu Leu Asn145 150 155 160Asn Phe Tyr Pro Arg Glu Ala Lys Val
Gln Trp Lys Val Asp Asn Ala 165 170 175Leu Gln Ser Gly Asn Ser Gln
Glu Ser Val Thr Glu Gln Asp Ser Lys 180 185 190Asp Ser Thr Tyr Ser
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp 195 200 205Tyr Glu Lys
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu 210 215 220Ser
Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230
23537237PRTArtificial SequenceK09A-L-16 light chain full
lengthsig_peptide(1)..(19) 37Met Ala Pro Val Gln Leu Leu Gly Leu
Leu Val Leu Phe Leu Pro Ala1 5 10 15Met Arg Cys Glu Ile Val Leu Thr
Gln Ser Pro Leu Ser Leu Pro Val 20 25 30Thr Pro Gly Glu Pro Ala Ser
Ile Ser Cys Arg Ala Ser Lys Gly Val 35 40 45Ser Thr Ser Gly Tyr Ser
Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly 50 55 60Gln Ser Pro Gln Leu
Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly65 70 75 80Val Pro Asp
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 85 90 95Lys Ile
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln 100 105
110His Ser Arg Asp Leu Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu
115 120 125Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro
Pro Ser 130 135 140Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val
Cys Leu Leu Asn145 150 155 160Asn Phe Tyr Pro Arg Glu Ala Lys Val
Gln Trp Lys Val Asp Asn Ala 165 170 175Leu Gln Ser Gly Asn Ser Gln
Glu Ser Val Thr Glu Gln Asp Ser Lys 180 185 190Asp Ser Thr Tyr Ser
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp 195 200 205Tyr Glu Lys
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu 210 215 220Ser
Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230
23538237PRTArtificial SequenceK09A-L-17 light chain full
lengthsig_peptide(1)..(19) 38Met Ala Pro Val Gln Leu Leu Gly Leu
Leu Val Leu Phe Leu Pro Ala1 5 10 15Met Arg Cys Asp Ile Val Met Thr
Gln Thr Pro Leu Ser Leu Pro Val 20 25 30Thr Pro Gly Glu Pro Ala Ser
Ile Ser Cys Arg Ala Ser Lys Gly Val 35 40 45Ser Thr Ser Gly Tyr Ser
Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly 50 55 60Gln Ser Pro Gln Leu
Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly65 70 75 80Val Pro Asp
Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu 85 90 95Lys Ile
Ser Arg Val Glu Ala Glu Asp Val Gly Leu Tyr Tyr Cys Gln 100 105
110His Ser Arg Asp Leu Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu
115 120 125Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro
Pro Ser 130 135 140Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val
Cys Leu Leu Asn145 150 155 160Asn Phe Tyr Pro Arg Glu Ala Lys Val
Gln Trp Lys Val Asp Asn Ala 165 170 175Leu Gln Ser Gly Asn Ser Gln
Glu Ser Val Thr Glu Gln Asp Ser Lys 180 185 190Asp Ser Thr Tyr Ser
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp 195 200 205Tyr Glu Lys
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu 210 215 220Ser
Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235
* * * * *
References